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PROTEIN RESURFACING TO IDENTIFY MACROMOLECULAR ASSEMBLIES 
 
 
              Protein engineering is an emerging discipline that dovetails modern molecular biology 
techniques with high-throughput screening, laboratory evolution technologies, and computational 
approaches to modify sequence, structure, and in some cases, function and properties of proteins. 
The ultimate goal is to develop new proteins with improved or designer functions for use in 
biotechnology, medicine and basic research. One way to engineer proteins is to change their 
solvent exposed regions through focused or random ‘protein resurfacing’. Here, I describe several 
approaches towards the development of synthetic proteins with new properties and function, 
including resistance to aggregation, increased solubility, and potent and selective macromolecule 
recognition. The first part of this thesis describes the use of protein supercharging to develop a 
split-superpositive GFP reassembly assay that is more efficient, faster, and more robust than 
previously described variants, largely due to increased resistance to aggregation. The second part 
of this thesis describes the use of shape complementarity, protein resurfacing, and high-throughput 
screening to evolve the first potent and selective protein-based inhibitor of the oncoprotein 
gankyrin. Concomitant with this work, I also describe a protein grafting strategy to identify a 
soluble mimic of S6 ATPase, which is subsequently used to characterize the S6 ATPase/gankyrin 
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Proteins possess properties that make them well suited for applications in basic research 
and clinical settings. Their large size, well-defined and complex structure, and functional group 
diversity (by virtue of the proteinogenic amino acids) often allows proteins to perform complex 
processes, foremost among them being catalysis, and molecular recognition of small-molecule, 
peptide, protein, or nucleic acid binding partners. With the advent of modern molecular biology 
came the ability to alter the genes that encode proteins. The fusion of molecular biology techniques 
to control or alter protein sequence, and high-throughput screening or selection methods to identify 
those few proteins with a desired function, has led to an explosion in the number of non-natural 
proteins with tailored properties. Alteration of protein sequence in an effort to generate improved 
or new function can be divided into three general areas: structure guided and focused engineering 
of a few amino acids within a catalytic pocket or of known function; randomized extensive 
mutagenesis of the entire protein sequence; or focused extensive mutagenesis of residues that 
reside on the protein surface. Here, we generally refer to the last approach (which sometimes 
precedes optimization by randomized mutagenesis) as protein resurfacing (Figure 1.1). As the 
reader will find below, protein resurfacing can endow a number of important properties and 
functions, including potent and selective recognition of macromolecules, increased stability, 
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solubility, and expression in non-natural hosts, resistance to aggregation, penetration of 
mammalian cells, and reduced immunogenicity. 
 
1.2 Resurfacing Proteins to Endow New Recognition 
Recognition is central to biology, and thus central to controlling biology. Historically, 
small-molecules (molecular weight <800 Da) have been used to modulate cell function and fate 
through potent and selective recognition of a macromolecule – often a protein. However, upwards 
of 90% of the proteome is deemed ‘undruggable’ by traditional small-molecules, by virtue of the 
fact that most proteins do not possess exposed hydrophobic small-molecule binding pockets.1 
Proteins offer a possible solution to recognition and modulation in areas of the proteome that 
stymie small-molecules. With this in mind, as well as the desire to better understand the molecular 
dictates of protein-protein interactions (PPIs), researchers have established research programs to 
identify, optimize, and interrogate these macromolecular assemblies.  
When initiating an effort to develop a new PPI, the first question one needs to answer is 
“what protein scaffold should I resurface in order to achieve new recognition?” A probable first 
response is an antibody. After all, our immune system uses antibodies as a molecular recognition 
framework to seek out, recognize, and facilitate the destruction of invaders.2 However, antibodies 
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and their fragments are not necessarily the best answer. First, anyone who has ever run a Western 
blot knows that not all antibodies are the same. Some have good target affinity, while others are 
relatively poor and promiscuous binders. Given the diversity of structure within the proteome, it 
is unlikely that one solution (sequence optimization of loop residues within the Fab fragment of 
an antibody) is a one-size-fi ts-all solution to potent and selective recognition. In addition, full 
length antibodies and antibody fragments generally express poorly in E. coli and are aggregation-
prone, leaving researchers searching for alternatives.3–5  
 Minimalized antibodies and antibody mimics that—like full length antibodies—rely on 
optimization of loop residues to achieve new affinity include fibronectin-based domains 
(monobodies6), camelid-derived nanobodies7, kunitz domains8, and lipocalins9. An excellent 
review has been written on the topic of minimalized immunoglobulin and non-immunoglobulin 
protein scaffolds that are evolvable (amenable to extensive resurfacing to achieve new 
recognition).10 In cases where loop optimization (through the use of antibodies and their structural 
mimics), computational design, or principles such as shape complementarity do not define a 
starting point, scaffolds highly amenable to mutagenesis, which display structured features, can be 
utilized. One such scaffold is a small three -helix bundle protein derived from the B domain of 
staphylococcal protein A, marketed as an affibody.11 Resurfaced affibodies have been generated 
to bind a diverse array of protein surfaces. As shown in Figure 1.2A, researchers often resurface 
two of the three -helices on an affibody scaffold. In one representative example, researchers used 
laboratory evolution based resurfacing to identify an affibody that binds a previously untargeted 
epitope on domain III of human epidermal growth factor receptor 2 (HER2), a protein 
overexpressed in ~30% of all breast and ovarian cancers—with exceptional affinity (KD ~20 pM, 
Figure 1.2B).12,13  
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Randomization and optimization of binding loops, within antibodies, antibody fragments, 
or non-immunoglobulin antibody mimics, is a reasonable starting point when little is known about 
the structure of the biopolymer being targeted. However, in other cases, structural features of the 
target, or efforts to optimize an existing low affinity complex, can guide or simplify selection of 
the starting protein scaffold. In these cases, researchers are given freedom to move beyond the 
(potential) confines of the antibody or non-immunoglobulin antibody mimic paradigm. While the 
literature is full of excellent case studies, we have selected representative examples that showcase
resurfacing of ‘privileged’ protein scaffolds, using existing structural features, shape-
complementarity, or optimization of a low affinity complex between the scaffold and target, as a 
design principle and starting point rationale. While the majority of cases, in the literature and our 
selected examples, use high-throughput screening or laboratory evolution to endow new 
recognition through protein resurfacing, computational approaches play an increasingly significant 
role in this field, and representative examples are included in this chapter. 
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There is wide interest in the molecular dictates of helical assembly, controlling such 
assemblies, and their role in various biological processes—including disease-relevant processes. 
Thus, methods for displaying and optimizing the surface of a helix, through resurfacing, is a focus 
of current protein science and chemical biology. The Kim14 and Schepartz15 labs have previously 
reported chemically synthesized miniature proteins or fragments with binding residues displayed 
on the surface of a helix. Proper positioning of residues on an existing helical structure, or 
optimization of the surface by high-throughput screening, can endow new recognition of these 
synthetic structures. More recently, our lab has used protein resurfacing (of a helix) to develop a 
protein that inhibits a ‘trimer-of-dimers’ helical assembly formed by gp41, which is required for 
HIV-1 infection of mammalian cells (Figure 1.3A and B). In particular, we used ‘helix-grafted 
display’, wherein many solvent exposed residues on a helix within the Pleckstrin Homology 
domain (PH domain) are mutated to mimic the HIV-1 gp41 C-peptide (Figure 1.3C). These helix 
resurfaced proteins selectively bind to a mimic of prefusogenic HIV-1 gp41.16  
It should go without saying that the molecular requirements for generating a potent and 
selective PPI is incredibly complex, and difficult to determine de novo. However, if you know 
something about the structure of the target you are going after, it makes sense that shape-
complementarity be a principal component of strategy to develop a binder. After all, developing 
new PPIs is fundamentally about generating a surface or binding pocket that complements the 
target. Many labs, including ours, have explored the virtues of shape-complementarity as a design 
principle for developing new PPIs, and representative examples are presented below, as well as 
discussed in detail in chapters three and five. 
Kuhlman and co-workers used shape-complementarity and computational design to 
generate a small, helical bundle protein that binds a hydrophobic region on p21-activated kinase 1 
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(PAK1, Figure 1.4, hydrophobic region is highlighted in blue).17 The human hyperplastic discs 
protein (HYP) scaffold they chose possessed the general size and shape to fit the desired cleft on 
PAK1. DDMI interface software was used to dock HYP onto PAK1, followed by protein 
resurfacing (highlighted in red), guided by Rosetta18, to computationally optimize the complex. 
One protein (termed ‘Spider Roll’) bound the targeted hydrophobic region on PAK1 with modest 
affinity (KD ~100 M Figure 1.4), representing one of the first examples of a de novo designed 
PPI based on shape complementarity.   
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In a conceptually similar effort, Baker, Karanicolas, and coworkers recently co-enginered 
a PPI by combining shape-complementd proteins, computational design, and directed evolution.19 
After choosing an in silico designed ankyrin repeat protein (this structural class is described in 
detail in chapter three), which they call Pdar, they used PatchDock20 t  screen 37 protein scaffolds 
for shape-complementarity to the largely hydrophobic binding face of the target. These researcher  
then used in silico protein resurfacing (Rosetta18,21) of the putative binding face. The best 
resurfaced protein, called Prb, binds Pdar with excellent affinity (KD ~140 nM). Subsequent 
resurfacing (by laboratory evolution) on the anticipated ankyrin repeat binding surface of Prb, and 
the concave face of Pdar, resulted in a very high affinity complex (KD ~180 pM).  
The above examples largely rely on targeting a hydrophobic surface on a protein, which is 
less complex than achieving recognition of a surface that is more polar, and as such likely requires 
the generation of well-defined hydrogen binding, ion-pair, and salt-bridge interactions. Toward 
the goal of achieving a new PPI that does not principally rely on hydrophobic effects to drive 
assembly, Baker and coworkers dovetailed computational docking (PatchDock20 and Rosetta 
Dock18,21) of shape-complementary scaffolds and directed evolution-based protein resurfacing to 
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identify a binding partner that recognizes a complex and highly charged surface on hen egg 
lysozyme (HEL). The resulting protein tightly binds HEL (KD ~3 nM), and inhibits lysosomal 
activity.22  
A majority of this thesis describes the use of shape complementarity as a protein design 
principle to target large, hydrophilic surfaces of a protein class (ankyrin repeats) that is extremely 
challenging from a molecular recognition standpoint. This work is discussed in chapters three and 
five. 
 
1.3 Protein Resurfacing to Alter Target Specificity and Reduce Binding Promiscuity 
Towards the goal of better understanding PPIs, protein resurfacing methods have been used 
extensively to alter (as opposed to merely broadening) target selectivity and reduce binding 
promiscuity. A few seminal examples are discussed below.   
Prolactin is a human growth hormone (hGH) homolog that has very low affinity for the 
hGH receptor. In an early and seminal contribution to the field of protein resurfacing to endow 
new recognition, scientists at Genentech integrated (and later optimized) 9 residues from wild-type 
hGH—that are critical to hGH receptor recognition—into the prolactin scaffold. As a result of 
resurfacing the hGH binding face, this team of researchers (led by Jim Wells) generated an hGH 
binding prolactin mutant that bound the hGH receptor ~10,000-fold better than wild-type prolactin 
(KD ~ 2 nM) , and only ~6-fold lower than hGH.23 
In other efforts, protein resurfacing has been used to decrease target promiscuity and direct 
recognition to a single target. For example, in a 2003 study, Shifman and Mayo used a structure-
based computational rotamer optimization method (ORBIT) to narrow down and optimize peptide 
recognition for calmodulin (CaM) – a messenger protein that promiscuously binds a multitude of 
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peptide sequences. In particular, these researchers focused on surface and boundary CaM residues 
to design a resurfaced CaM that potently and selectively binds smooth muscle myosin light chain 
kinase (smMLCK). Starting from a previously described variant24, iterative rounds of design and 
analysis resulted in improved selectivity. While both the wild-type and resurfaced CaM proteins 
bind smMLCK peptide with excellent affinity (KD ~ 2 nM for each), the evolved protein binds 
smMLCK with ~7-fold selectivity over other CaM targets, by virtue of the dramatically resurfaced 
binding face that was optimized for this specific ligand (Figure 1.5).25 
More recently, Reynolds and co-workers employed computational methods (EGAD26) to 
design a -lactamase inhibitor protein (BLIP) with increased affinity and specificity for SHV -
lactamase. BLIP can bind to and inhibit several -lactamases, but has the lowest affinity for SHV-
1 (KD ~1.7 M). Comparing the crystal structures of BLIP/TEM-1 (KD ~1.3 nM) and BLIP/SHV-
1, the researchers focused on cluster 2 (C2), and found three mutations that strongly favor SHV-1 
binding (E73M, S130K, S146M). The BLIP variant increased affinity for SHV-1 almost 400-fold 
(KD ~4.6 nM), while reducing affinity for TEM-1 greater than 20-fold (KD ~27 nM).27 
 
1.4 Protein Resurfacing to Improve Protein Expression, Stability, Solubility, and Generate 
Resistance to Aggregation 
 Perhaps the most widely used protein over the last few decades is Green Fluorescent 
Protein (GFP), and is an excellent example of how protein resurfacing can optimize expression, 
stability and solubility. GFP is a 238 amino acid protein that forms a -b rrel structure (Figure 
1.6).28 Almost everyone is familiar with work (principally done by Tsien and coworkers) to alter 
spectroscopic properties of the GFP chromophore – sulting in the fruit-based color palette of 
fluorescent proteins we currently enjoy.29 However, before this Nobel prize winning achievement, 
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research on GFP was hindered by challenges with its expression and aggregation, largely due to 
homodimerization and instability at high concentrations.28 Coupling mutagenesis and 
fluorescence-activated cell sorting (FACS), researchers at Affymax discovered two solvent 
exposed mutations, F99S and M153T, which resulted in a GFP variant with significantly improved 
solubility (referred to as ‘cycle 3 mutations, Figure 1.6, blue).30 In 2006, Waldo and coworkers 
used mutagenesis and flow cytometry screening to identify a variant with optimized folding (which 
they linked to fluorescence intensity). Interestingly, this mutant, which they call ‘superfolder GFP’ 
(sfGFP) contains five solvent exposed mutations (S30R, Y39N, N105T, I171V, A206V, Figure 
1.6, red), and this protein resurfacing led to a GFP mutant that only exists in monomeric form. 
Further underlining the importance of protein resurfacing, the robust folding kinetics of 
superfolder GFP is thought to derive from both an increase in surface stabilizing interactions and 
inhibition of dimer formation.31 
In an intramolecular context, the delicate balancing act called protein folding is principally 
driven by the collapse of hydrophobic residues to form a hydrophobic core.32 However, in an 
intermolecular context, the same basic process of hydrophobic driven assembly can result in 
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aggregation – a major issue for protein therapeutics, and a culprit in some human diseases, 
including Alzheimers, amyloidosis, and prion diseases.33 Researchers have developed methods—
founded in protein resurfacing—that seek to generate proteins resistant to aggregation. A detailed 
discussion of our lab’s contribution in this field is discussed in chapter two.  
 Liu and coworkers recognized a well-established relationship between the solubility of 
natural proteins and their overall net charge. Using a process they call ‘protein supercharging’—
extensive mutagenesis of solvent exposed residues to either positively charged (lysine or arginine) 
or negatively charged (aspartic or glutamic acid)—they hypothesized that resistance to aggregation 
could be created. Starting from superfolder GFP (-7 theoretical charge, termed starting GFP or 
stGFP), they selected residues for mutation using a computational method (average neighboring 
atoms per side chain atom, AvNAPSA), resulting in GFP mutants with a theoretical net charge 
that ranged +15 to +48, and –25 to –30 (Figure 1.7A). Amazingly, supercharged GFP mutants 
with a theoretical net charge of +36 or -30 resist aggregation and regain fluorescence aft r h at 
denaturation at 100 °C followed by slow cooling. In contrast, the stGFP scaffold aggregates under 
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identical conditions (Figure 1.7B). Two additional proteins, streptavidin and glutathione-S-
transferase (GST), were also shown to tolerate supercharging and resist aggregation to some 
degree.34   
Recently, Ellington and coworkers applied supercharging to aggregation-prone short chain 
antibody variable fragments (scFv).35 Starting from an anti-MS2 scFv (+7.5 theoretical net charge), 
the researchers computationally designed supercharged variants ranging from -19.5-+33.5 
theoretical net charge. One supercharged mutant, K-pos-1 (+15.5 theoretical net charge), generated 
improved resistance to heat denaturation and aggregation, retaining ~70% binding activity after 
being heated at 70 °C, while the wild-type completely lost binding activity. Additionally K-pos-1 
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was less prone to aggregation than the wild-type protein when stored at 4 °C in phosphate-buffered 
saline (PBS), as determined by dynamic light scattering (DLS). Despite extensive mutagnesis, as 
a result of supercharging, K-pos-1 retained affinity for MS2, and actually bound this protein ~36 
times tighter than the wild-type protein (KD ~1 nM and 36 nM, respectively), perhaps due to 
stabilization of the protein complex. 
Supercharging has been used to solubilize membrane-bound proteins, which are 
notoriously difficult to express in a soluble form, due to solvent-exposed hydrophobic patches that 
normally take refuge in the lipid bilayer membrane. Researchers in the Weiss lab used a 
combinatorial supercharging and phage display to optimize residues in the hydrophobic patch. 
This resulted in a supercharged and soluble mutant of the membrane protein caveolin, which 
expresses in large quantities in E. coli and retains affinity for three binding partners of the wild-
type protein.36 
 
1.5 Protein Resurfacing to Endow Mammalian Cell Penetration 
 One major challenge to the broader use of proteins in biomedical applications is their 
general inability to efficiently cross the lipid bilayer of mammalian cells and access the cytosol or 
nucleus. Thus, most current protein drugs and basic research tools target infectious reagents, 
secreted receptors, and disease-relevant receptors that reside on the surface of the cell or the 
extracellular matrix. Efforts to unlock the full potential of proteins in biomedical applications by 
enabling potent and functional cell penetration have been a major focus of modern biologics 
research. Incorporation of polycationic linkages—such as polyarginine and the trans-activating 
transcriptional activator peptide (TAT) from HIV-1—have previously been described as a means 
to enable cell penetration of various cargo, including proteins.37–39 More recently, researchers have 
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used protein resurfacing to generate polycationic features on the protein surface. For example, 
Raines and Fuchs reported that ‘arginine grafting’ of GFP—mutagenesis of clustered solvent 
exposed amino acids to arginine— nables cellular uptake (Figure 1.8A).40 While the arginine 
grafted GFP is internalized, it appears as punctate foci in fluorescence microscopy images – 
suggesting encapsulation of the internalized protein within endosomes. While such encapsulation 
might limit the utility of most internalized proteins, high turnover enzymes might be an outlier, 
since only a small amount of the protein needs to access the cytosol to alter cell function and fate. 
In the Raines lab, arginine grafting has been used to endow uptake of proteins with possible 
therapeutic utility. In particular, effort was focused on generating resurfaced ‘arginine grafted’ 
variants of ribonuclease A (RNase A), which, if delivered to the cytoplasm is cytotoxic to 
mammalian cells. Installation of two arginine mutations (E49R, D53R), distant from the catalytic 
site on RNase A, resulted in cell penetration and a 3-fold increase in cytotoxicity in K-562 
leukemia cells.41  
Onconase, an amphibian ribonuclease with cytotoxicity for tumor cells, enters cells due to 
a lysine-decorated surface. Previous research showed that arginine is more effective as a 
transporter across the cell membrane, compared to lysine.37,39 In an effort to improve cell uptake 
potency, Raines and coworkers created an arginine grafted variant, wherein all ten solvent-exposed 
lysines are mutated to arginine. Arginine-grafted Onconase (R-Onc) was internalized ~3-fold more 
efficiently compared to the wild-type protein; however, no appreciable increase in cytotoxicity 
was observed, potentially due to decreased stabilization and increased proteolytic degradation.42  
In addition to endowing resistance to aggregation, protein supercharging (in the positive 
direction) has been used to endow mammalian cell penetration. Researchers in the Liu lab found 
that resurfaced ‘supercharged’ GFPs with a theoretical net charge of +15, +25, and +36 potently 
15 
 
penetrate a variety of mammalian cell lines, in a charge-dependent manner. Similar to arginine 
grafted GFP, internalized protein appears as punctate foci in fluorescence miscroscopy images – 
suggesting that most of the internalized protein is encapsulated in endosomes (Figure 1.8B).43 
Nonetheless, not only does +36 GFP enter mammalian cells, the polycationic protein forms a 
complex with siRNA or plasmid DNA, and this complex resulted in the delivery of bound nucleic 
acids to mammalian cells.44  Liu and coworkers showed that +36 GFP can drag a fused protein 
into mammalian cells. Of particular note, when fused to +36 GFP, appreciable levels of  Cre-
recombinase is delivered to various mammalian cells or mouse retinal tissue, resulting in Cre-
dependent expression of DsRed2 or -galactosidase, respectively.43 More recently, Liu and 
coworkers have shown that resurfaced polyanionic GFP (-30 theoretical net charge), and fusions 
thereof, can be delivered to the interior of cells when pre-mixed with commercially available 
cationic lipids.45 Using up to a 1,000-fold lower dosage than +36 GFP fusions, these researchers 
were able to delivery various genome editing proteins into mammalian cells, including 
transcription activator-like nucleases (TALENs). Intracellular delivery of TALENs specific for the 
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neurotrophin-3 gene (NTF3) resulted in a ~7-fold increase in protein expression in just 4 hours. 
Additionally, -30 GFP-Cre fusions could be delivered to mouse inner ear cells, resulting in Cre-
dependent recombination of tdTomato in ~90% of outer hair cells.  
While these polycationic resurfacing methods endow potent cell penetration, a major 
challenge to their broader application is the lack of established and broadly applicable guidelines 
for this extensive mutagenesis. While computational tools can guide protein supercharging, 
relatively little is known about how to dramatically resurface a protein with a polycationic feature 
in a manner that does not dramatically alter or abolish its utility and/or function (stability, target 
affinity, expression in E. coli). In our experience, even structurally similar proteins respond 
differently to such extensive mutagenesis, and many proteins of therapeutic interest were not 
amenable to polycationic resurfacing. Perhaps a simpler approach is to focus effort on developing 
a single resurfaced polycationic, cell-penetrating, protein scaffold that is stable, expresses in E. 
coli, maintains the function of the original protein, but can be evolved to bind virtually any disease-
relevant intracellular target. 
In the context of this challenge, our lab very recently reported polycationic resurfaced cell-
penetrating nanobodies.46 The researcher team used three previously reported nanobodies that 
binds GFP47, HER248 or -lactamase49 (referred to as NB1, NB2, and NB3, respectively). Solvent-
exposed residues within the framework region—that are distinct from the complementary 
determining regions (CDR loops), where binding occurs, were mutated to either lysine or arginine 
(Figure 1.9A, blue spheres). When fused to GFP, all three polycationic resurfaced nanobodies 
(pcNB1-3) drag GFP into the cell, in a concentration-dependent manner. Interestingly, in contrast 
to arginine grafted or supercharged GFP, which appear as punctate foci, resurfaced nanobodies d  
not appear as such (Figure 1.9B-D), suggesting that appreciable amounts of these internalized 
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nanobodies might access the cytosol. This important aspect of cell uptake was further analyzed 
using a previously described lysis assay and Western blot.50 No appreciable amount of wild-type 
His6x labelled nanobody is found within the cytosolic extraction (Figure 1.9E, lanes 2-4). In 
contrast, internalized resurfaced His6x-nanobodies appear in the cytosol (Figure 1.9E, lanes 5-7). 
Thus, the polycationic resurfaced protein is capable of dragging another protein (GFP) into the 




1.6 Genetic or Chemical Protein Resurfacing to Modulate Immunogenicity 
Non-human proteins are often taken up by antigen-presenting cells (APCs), which in turn 
process and display small peptidic regions of that protein (9-15 amino acids).51 Some of these 
segments (referred to as T-cell epitopes) are recognized by major histocompatibility complex class 
II (MHC II ) as ‘non-self’, and can lead to the production of neutralizing antibodies.52 These 
antibodies are problematic, since they can diminish the concentration or existence of the biological 
therapeutic, or even worse, initiate a full on immune response that leads to potentially dangerous 
side effects.53  Thus, resurfacing as a means of removing T-cell epitopes to reduce immunogenicity 
is a major effort in the development and implementation of protein drugs. 
Removing B-cell epitopes (antibody-binding epitopes), although a potential companion 
strategy with T-cell epitope removal54–56, remains challenging, since it is requires knowing how 
anti-drug antibodies bind its target. In contrast, resurfacing to remove T-cell epitopes is 
independent of antibody recognition and is an established method for reducing protein 
immunogenicity. Critically, computational tools that scan for MHC II-binding T-cell epitopes in a 
protein sequence are available, and successful examples of T-cell epitope removal by dovetailing 
computational tools and extensive mutagenesis at the protein surface are provided below. 
Bacterial proteins are almost always highly immunogenic (elicit an immune response). 
Staphylokinase, a protein secreted from strains of Staphylococcus aureus, has potent thrombolytic 
activity in humans, and thus is of interest as a method to dissolve blot clots, but elicits an immune 
response. Warmerdam and co-workers identified six highly immunogenic regions within the 
protein, and employed in silico alanine-scanning of overlapping epitopes regions to focus 
mutation. Impressively, the immunogenicity of a variant with only four mutations reduced donors 
staphylokinase-specific T-lymphocytes to undetectable levels, compared to a positive response 
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with the wild-type proteins. This was the first example highlighting the ability to deimmunize a 
bacterial protein using T-cell epitope elimination.57,58 
Similarly, researchers in the Fiering, Bailey-Kellogg, and Griswold labs applied a 
structure-based deimmunization algorithm (EpiSweep59) to resurface Lysostaphin, a 
metalloprotease that binds and cleaves the cell wall of Staphylococcus aureus (Figure 1.10).59–61 
Using computation as a guide, these researchers identified a lysostaphin variant with 13 mutations 
that reduced anti-lysostaphin IgG titers after injection in transgenic DR4 mice up to ~1000-fold 
after two weeks, compared to treatment with the wild-type protein. Additionally, this mutant 
exhibited increased efficacy in the same mice challenged with a strain of methicillin-resistant 
Staphylococcus aureus (MRSA), highlighting the correlation between decreased immunogenicity 
and increased efficacy. 
Finally, T-cell epitope removal has been used to deimmunize potent toxins, which are 
regularly combined with antibody fragments for targeted delivery in cancers (often referred to as 
immunotoxins). Perhaps most notably, the Pastan lab, in collaboration with several other labs, 
combined Rosetta computational design and guided alanine mutagenesis to deimmunize a 38 kDa 
toxin derived from Pseudomonas exotoxin A. Using high-resolution mapping, predicted epitope 
content was lowered by 93% by removing eight T-cell epitopes with just six mutations, resulting 
in a ~90% decrease in T-cell response, while retaining cytotoxicity.62–64 
The above examples rely on altering the sequence of solvent exposed amino acids in order 
to suppress immunogenicity. An alternative strategy is to use chemical methods to modify the 
solvent exposed protein surface, to endow or improve function. In the context of suppressing 
immunogenicity, covalent attachment of polyethylene glycol to the protein surface (referred to as 
‘PEGylation’, Figure 1.11) has been used extensively.65–68 First discovered in the 1970’s, 
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PEGylation can be used to render proteins ‘invisible’ to the immune system, presumably by 
blocking recognition between immune system components and immunogenic solvent exposed 
protein surfaces. PEGylation can also dramatically reduce protease degradation and increase serum 
lifetime. Demonstrating the value of this chemical resurfacing method, a large number of FDA-
approved protein drugs are sold as PEGylated variants, including asparaginase (Oncaspar®), 
granulocyte colony-stimulating factor (Neulasta®), and interferon variants (Pegasys® as one 
example).69 More recently, researchers aimed to expand the value of covalent protein resurfacing 
as a means to endow new properties, including improved suppression of immunogenicity. One 
promising strategy is N-linked glycan conjugation, which is based on a natural defense mechanism 
used by certain viruses to evade the immune system.70 As an example, researchers in the Sanders 
lab recently ‘immunosilenced’ immunogenic trimerization domains by incorporation of four N-






Proteins have properties (large size and associated ability to bind a large surface area, well-
defined structure, functional group diversity) hat make them well suited as basic research tools 
and drugs, particularly in spaces that challenge small-molecule centered discovery. Moreover, 
modern molecular biology, and high-throughput screening and laboratory evolution technologies 
enable researchers to screen billions of proteins for a desired function – something that is virtually 
impossible in the small-molecule world. The truth is that using biologics in clinical applications is 
on the rise (half of the current top 20 selling drugs are biologics), and most of the proteome is not 
amenable to potent and selective modulation by small-molecules. However, using biologics in 
basic research and clinical settings introduces a host of challenges. Protein resurfacing has, a d
will, continue to play a pivotal role in generating novel proteins with a desired function, such as 
potent and selective recognition and modulation of a disease-relevant receptor, and can be used to 
improve properties relevant to biomedical applications. In this chapter, we showed the reader that 
protein resurfacing—extensive amino acid mutagenesis or covalent modification—can be done to 
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improve selective macromolecular recognition, expression, solubility and stability, endow 
resistance to aggregation, enable penetration of mammalian cells, and modulate immunogenicity. 
Moreover, we have shown that protein resurfacing methods have the potential to be combined to 
achieve a wide range of favorable characteristics. Clearly, we have only begun to ‘scratch the 
surface’ of protein resurfacing. As more and more biologics (overwhelmingly proteins) enter the 
market as FDA approved drugs, protein resurfacing will clearly play a prominent role in generating 
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Split-Superpositive Green Fluorescent Protein Reassembly is a Fast, 
Efficient, and Robust Method for Detecting Protein-Protein 








 In this work, led by third year graduate student Brett Blakeley, I assisted in gene 






  The development of methods that rapidly and accurately identify interactions between 
structurally diverse proteins and/or peptides is key to the development of new proteins with novel 
function, as well as proteomics.  Techniques such as immunoprecipitation, mass spectrometry, 
affinity purification, and protein microarrays have been used to identify interactions involving 
proteins and/or peptides in vitro.1 However, these approaches are laborious (typically requiring 
expression and purification steps for each protein or peptide studied), low-throughput, are often 
limited to high-affinity interactions, and can involve complicated and/or expensive equipment. 
Perhaps most importantly, these methods do not provide any strong information on the likelihood 
of identified interactions occurring in vivo. 
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  Popular in vivo approaches to identify and study interactions involving proteins and/or 
peptides include two-hybrid screening and split-protein reassembly.2,3 Perhaps the most common 
limitation of two-hybrid screening is the significant number of false positive results and the need 
for nuclear localization of the interacting protein or peptide. In addition, visualization of an 
interaction using two-hybrid methods requires subsequent transcription and translation of a 
reporter protein, which increases the overall length and complexity of the screen. 
  Split-protein reassembly, also known as a protein fragment complementation assay (PCA), 
offers an alternative to two-hybrid methods, and has been used to identify and study interactions 
involving proteins and/or peptides in prokaryotic and eukaryotic cells. In a split-reporter 
reassembly experiment, a reporter protein is split into two fragments and fused to possible 
interacting peptide and/or protein partners. In the absence of fused binding partners, the split-
reporter fragments do not reassemble and reporter activity is not observed.  However, if the fused 
proteins and/or peptides have affinity for one another, that interaction brings the split-reporter 
fragments into close proximity, those fragments associate and/or fold, and a functional reporter 
protein is generated. 
  Reporter proteins typically fluoresce, catalyze a colorimetric or fluorescent reaction, or 
endow the host cell with resistance to an exogenous toxin. Common split-reporter proteins used in 
E. coli, S. cerevisiae, and mammalian cells include -lactamase4, -galactosidase5, dihydrofolate 
reductase (DHFR)6, ubiquitin7, and Green Fluorescent Protein (GFP)8. In many ways, GFP is 
perfectly suited as a reporter in a PCA experiment. Unlike enzymatic reporter proteins that catalyze 
the formation of a fluorescent or colorimetric molecule from a precursor, or catalyze the 
degradation of an exogenous toxin, GFP does not require the addition of exogenous reagents in 
order to generate a signal. In addition, GFP expresses, folds, and fluoresces in a large number of 
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cell types and intracellular compartments, and is generally resistant to proteolytic degradation.9 
Since the formation of a fluorescent chromophore in GFP is irreversible, split-GFP reassembly can 
be used to examine weak interactions with dissociation constants (KD) as high as 1 mM.10 
  Despite the operational simplicity of split-GFP reassembly, the susceptibility of GFP 
fragments to aggregation limits its more general use.10 Aggregation of split-GFP fragments lowers 
the cellular concentration of competent split-GFP fusions. As a result, the probability of interacting 
pairs finding each other in a complex cellular environment is decreased and the overall number of 
possible interaction-dependent GFP reassembly events is lowered. Unsurprisingly, interaction-
dependent split-GFP reassembly can be slow and inefficient (see below). Slow evolution of 
interaction-dependent GFP fluorescence increases the time required to identify an interaction and 
low total cell fluorescence increases the difficulty of isolating “hits” from a large library of possible 
interacting protein and/or peptide pairs. 
Split-sg100 GFP, a split-GFP reporter prepared from an enhanced stability variant, is a 
commonly used system for identifying and studying interactions involving proteins and/or 
peptides.8,10 Split-sg100 GFP reassembly typically requires 24 - 72 hours in order to generate 
visible levels of cellular GFP fluorescence.10 Since the stability of GFP fragments (or most proteins 
and/or peptides, for that matter) typically decreases as a function of increased temperature, 
interaction-dependent reassembly screens using split-sg100 GFP fusions are often performed well 
below physiological temperature (typically 20 °C - 30 °C). Since binding interactions are often 
stabilized at lower temperatures, it is reasonable to anticipate that some interactions identified at 
lower temperatures may not take place at physiological temperature (37 °C). Therefore, the number 
of false positive results may be significant. 
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 As discussed in detail in chapter one, researchers have noted a strong correlation between 
protein solubility and theoretical net charge11, and have taken advantage of this correlation through 
a protein resurfacing process referred to as supercharging. Researchers in the Liu lab developed a 
positively supercharged variant of GFP (+36 GFP) with enhanced stability and resistance to 
aggregation, while maintaining similar fluorescence characteristics as wild-type GFP.12 With this 
technology in mind, we hypothesized that supercharging could be applied to split-GFP reassembly 
to improve on the limitations discussed above. We postulated that the individual GFP fragments 
should be substantially more resistant to aggregation in comparison to non-supercharged 
counterparts, which have low theoretical net charge (-4 for each fragment), and that higher 
concentration of soluble split-GFP fragments would therefore be present in the cell. If this effect 
outweighs any inhibitory effect of the association rate of the GFP fragments due to electrostatic 
repulsion, faster and more efficient split-superpositive GFP (split-s GFP) reassembly would 
expected (summarized in Figure 2.1). In addition, we hoped that split-spGFP fragments might 
increase the solubility of fused proteins and peptides, potentially expanding the scope of split-GFP 
reassembly to proteins and peptides that are themselves susceptible to aggregation. 
The theoretical net charge of sg100 GFP is -8.  When sg100 GFP is split into N- and C
terminal fragments, each has a theoretical net charge of -4 (Figure 2.1A).  In order to compare the 
efficiency of split-sg100 GFP reassembly to a split-supercharged GFP variant, we prepared N-
terminal and C-terminal superpositive GFP (spGFP) fragments with net theoretical charges of +24 
and +10, respectively (Figure 2.1B).  This split-spGFP (based on +34 GFP) is similar to the 
supercharged GFP reported by Liu and coworkers.12 We cloned the spGFP N- and C-terminal 
fragments into pET11a and pMRBAD plasmids, respectively, as fusions to high-affinity 
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antiparallel leucine zipper peptides, which have been used extensively as a positive control to 
measure interaction-dependent reassembly of split-sg100 GFP fragments.8,10 
 
2.2 Split-spGFP Reassembly Produces a Brighter Fluorescence Signal  
  We co-transformed BL21 E. coli (DE3) with NGFP-Z pET11a and Zʹ-CGFP pMRBAD, 
where Z and Zʹ are the positive control leucine zipper peptides and GFP is an N- or C-terminal 
fragment of either sg100GFP or spGFP. In order to compare the maximum cell fluorescence 
generated as a result of split-GFP reassembly, E. coli were induced to express the split-GFP-Z 
fusions with isopropyl -D-1-thiogalactopyranoside (IPTG) and arabinose, incubated at 25 °C, and 
analyzed by flow cytometry. For both systems, maximum cell fluorescence was reached after 12 
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hours.  Consistent with our hypothesis, the mean cellular fluorescence in E. coli expressing the 
split-spGFP positive control fragments increased 75-fold compared to uninduced cells, while mean 
cellular fluorescence in E. coli expressing the split-sg100 GFP positive control fragments only 
increased 2.3-fold, and fluorescence distribution was broad (Figure 2.2A). When E. coli 
containing each set of positive control plasmids were incubated at 30 °C for 18 hours, conditions 
previously reported10,13, much brighter cell fluorescence was observed visually in E. coli 
expressing the split-spGFP positive controls (Figure 2.2B). E. coli containing the split-sg100 GFP 
or split-spGFP constructs does not generate significant cell fluorescence in the absence of IPTG 
and arabinose induction reagents (Figure 2.2A).  Taken together, these results clearly show that 
split-spGFP reassembly is much more efficient than split-sg100 GFP reassembly.  This 72.8-fold 
increase in cell fluorescence drastically simplifies the identification of interacting pairs when using 




2.3 Split-spGFP Reassembly Facilitates Faster Signal Generation 
Next, we measured the rate of split-GFP reassembly in E. coli expressing the split-sg100 
GFP or split-spGFP positive controls. E. coli was induced, incubated at 25 °C, and cell 
fluorescence was measured by flow cytometry after 1, 2, and 3 hours. The results of these 
experiments are shown in Figures 2.3A and 2.3B. One hour after incubation, no appreciable 
increase in cell fluorescence is observed in E. coli expressing the split-sg100 Z peptide positive 
control fusions. In contrast, after the same period of time, a 5-fold increase in mean cell 
fluorescence was observed in E. coli expressing the split-spGFP positive control fusions. After 
two hours, no appreciable change in fluorescence was observed in E. coli expressing the split-
sg100 GFP leucine zipper fusions, while a 15-fold change was observed for the split-spGFP 
system. Three hours after induction, a very modest 1.2-fold increase in mean cell fluorescence was 
observed as a result of split-sg100 GFP reassembly. After the same period of time, a 28-fold 
increase in mean cell fluorescence was observed in E. coli expressing the split-spGFP positive 
controls. Taken together, these data clearly show that split-spGFP reassembly is much faster than 
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split-sg100 GFP reassembly. This increase in reassembly rate drastically shortens the experimental 
time needed to visualize and identify an in cellulo interaction. Interaction-dependent changes in 
cell fluorescence as a result of split-spGFP reassembly are easily observed by flow cytometry in 
as little as one hour. 
 
2.4 Comparison of Split-spGFP and Split-frGFP Assembly Efficiency  
  Magliery and coworkers recently described split-folding reporter-GFP (split-frGFP), 
which is constructed from a GFP variant optimized to fold robustly.13,14 When fused to antiparallel 
leucine zipper peptides, split-frGFP reassembly was qualitatively determined to be faster and more 
efficient than split-sg100 GFP reassembly. We compared the efficiency and rate of GFP 
reassembly for split-frGFP and split-spGFP by flow cytometry. 
  As shown in Figure 2.4A, when incubated at 25 °C for 12 hours, which is when maximum 
fluorescence is observed for both systems, E. coli expressing the split-frGFP and split-spGFP 
positive control leucine zipper fusions both exhibit high levels of cell fluorescence. However, 
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maximum mean cell fluorescence was 22% brighter in E. coli expressing the split-spGFP positive 
controls (Figure 2.4A).  As seen in Figure 2.4B, reassembly of the split-spGFP positive controls 
is faster than reassembly of split-frGFP. One hour after induction, E. coli expressing the split-
spGFP positive control fusions was 34% more fluorescent than cells expressing the split-frGFP 
fusions. 
 
2.5 Split-spGFP Reassembly is Brighter at Physiological Temperature 
  As stated previously, reassembly systems that operate efficiently at 37 °C are ideal, since 
interactions identified at this temperature are more likely to occur at physiological conditions. As 
shown in Figures 2.5A and 2.5B, interaction-dependent split-spGFP reassembly is more efficient 
than split -frGFP reassembly at 37 °C. When incubated for 24 hours, E. coli expressing the split-
spGFP positive control antiparallel leucine zipper fusions were 24% more fluorescent than cells 
expressing the split-frGFP fusions. The increase in split-spGFP reassembly efficiency at 37 °C 
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demonstrates the robustness of this reporter system and its use to identify interactions at 
physiological conditions. 
 
2.6 Split-GFP Reassembly is Orientation-Independent  
  Split-GFP reassembly is often used to study interactions involving relatively short helical 
peptides such as leucine zipper interactions or simple protein - protein interactions involving 
helical assembly. In many ways, an interaction involving two leucine zipper peptides is ideal for 
split-GFP reassembly because the antiparallel leucine zipper interaction perfectly aligns sp t-GFP 
fragments for reassembly (Figure 2.6A). In order to be used more generally, split-GFP reassembly 
systems need to efficiently detect an interaction involving proteins with additional structural 
complexity. In addition, unlike leucine zipper interactions, most interactions will not have 
perfectly aligned N- and C-termini between the interacting pairs. The ability to detect interactions 
that involve complex protein - protein interactions where the N- and C-termini of those proteins 
are not perfectly aligned for split-GFP reassembly is critical to more general use, as well as for use 
in high-throughput screening of protein libraries.   
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  In order to compare the efficiency of protein - protein interaction detection using split-
spGFP and split-frGFP, we fused their respective N- and C-terminal fragments to Pdar and Prb, a 
high-affinity (KD ~180 pM) designed protein - protein interaction discussed in chapter one.15 As 
seen in Figure 2.6B, the N- and C-termini of Pdar and Prb are not perfectly aligned for split-GFP 
reassembly. E. coli harboring either NspGFP-Prb/Pdar-CspGFP or NfrGFP-Prb/Pdar-CfrGFP 
plasmids were induced with IPTG and arabinose, and Pdar/Prb interaction-dependent cell 
fluorescence was monitored at 37 °C by flow cytometry. For both split-GFP systems, maximum 
cell fluorescence was reached after 12 hours. Cells expressing the split-spGFP Pdar/Prb fusions 
were 27% more fluorescent than cells expressing the split-frGFP Pdar/Prb fusions (Figure 2.7). 
This increase in cell fluorescence demonstrates the increased efficiency, utility, and robustness of 
split-spGFP reassembly. Based on these findings, we postulate that split-spGFP reassembly results 
from a high-effective molarity of complementary GFP fragments brought together by the PPI, 
rather than requiring an orientation-specific interaction to hold the fragments together (Figure 
2.8). This reassembly model therefore expands the scope of split-spGFP to PPIs that are 
orientation-independent, as compared to many other PCA methods, which are generally limited to 
ideal binding-partner orientation.  
  One potential concern we had was that the individual GFP fragments would exist in such 
high cellular concentrations, due to decreased aggregation, that they may reassemble independent 
of interacting fused proteins. Towards this end, we fused a pair of non-interacting protein partners, 
the ankyrin repeat protein gankyrin (discussed in chapter three)16 and Prb, to the C- and N-
fragments of spGFP, respectively. Flow cytometry was measured after 24 hours, comparing 
induced and uninduced E. coli, resulting in no appreciable change in GFP fluorescence (Figure 
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S2.4). This finding demonstrates that split-spGFP fragments do not spontaneously reassemble in 
the absence of a PPI. 
   
2.7 Conclusion  
The susceptibility of split-GFP fragments to aggregation has been suspected to play a 
significant role in decreasing the efficiency and rate of interaction-dependent reassembly.10 
Supercharged resurfaced proteins, including superpositive GFPs, have been shown to be resistant 
to aggregation.12 We constructed a split-superpositive GFP consisting of N- and C-terminal 
fragments that have theoretical net charges of +24 and +10, respectively. When fused to interacting 
antiparallel leucine zipper peptides, split-spGFP undergoes interaction-dependent reassembly 
faster and more efficiently than split -sg100 GFP and split-frGFP. Split-spGFP reassembly has been 
shown to efficiently detect formation of complexes involving interacting peptides or proteins a  
physiological temperature. Given its overall high efficiency and robustness, we anticipate that 
split-spGFP will find broad use in the proteomics, chemical biology, biochemistry, and biophysics 
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communities, and may be useful for identifying and/or studying interactions involving proteins or 
peptides that are themselves susceptible to aggregation. Furthermore, we expect that split-spGFP 
will be particularly useful for high-throughput screening applications, largely due to the increased 
rate of fragment reassembly and minimized loss of potential library members to aggregation. 
Towards this end, application of split-spGFP as a high-throughput screening tool is discussed 
further in chapter three. 
 
2.8 Methods 
Plasmid Construction Nsg100GFP-Z pET11a (NGFP-Z) and Zʹ-Csg100GFP pMRBAD (Zʹ-
CGFP) plasmids were generously provided from Professor Lynn Regan (Yale University). 
NfrGFP-Z pET11a and Zʹ-CfrGFP pMRBAD plasmids were generously provided from Professor 
Thomas Magliery (Ohio State University). The gene for spGFP was constructed (amino acid 
sequence of +36 GFP was kindly provided by Professor David Liu at Harvard University) using 
overlap polymerase chain reaction (PCR) and amplified (all primers purchased from Integrated 
DNA Technologies, IDT), and cloned into the NcoI and KpnI sites of a pET plasmid (all cloning 
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enzymes purchased from New England Biolabs, NEB).  From this deoxyribonucleic acid (DNA), 
a DNA sequence encoding the N-terminal fragment of spGFP (encoding amino acids 1-157) was 
amplified by PCR. This amplicon was double digested with NdeI and BamH1 and cloned into 
NGFP-Z pET11a, replacing NGFP (sg100), to create the new construct NspGFP-Z pET11a. The 
C-terminal fragment (CspGFP) was amplified from spGFP pET. This amplicon was double 
digested with NcoI and BsrG1 and cloned into Zʹ-CGFP pMRBAD, replacing CGFP, to create the 
new construct Ź-CspGFP pMRBAD. All constructs used confirmed by GENEWIZ DNA 
sequencing. 
  Plasmids encoding Pdar and Prb were generously provided by Professor David Baker 
(University of Washington). Plasmid encoding gankyrin was purchased from Addgene. Pdar and 
gankyrin were amplified, double digested with NcoI and AatII and cloned into -CfrGFP pMRBAD 
or –CspGFP pMRBAD, replacing Zʹ. Prb was amplified double digested with XhoI and BamHI 
and cloned into NfrGFP- pET11a or NspGFP- pET11a, replacing Z. 
Generation, Growth and Induction of E. coli Expressing Split-GFP Positive Control 
Plasmids To co-transform compatible pairs of plasmids (NGFP-Z pET11a and Zʹ-CGFP 
pMRBAD, NfrGFP-Z pET11a and Zʹ-CfrGFP pMRBAD, or NspGFP-Z pET11a and Zʹ-CspGFP 
pMRBAD), the construct containing the N-terminal fragment was transformed into chemically 
competent BL21(DE3) E. coli using a standard heat-shock protocol. These cells were then made 
electrocompetent by standard methods and transformed with the construct containing the 
respective complementary C-terminal fragment, using electroporation (1 mm cuvettes and 1.7 
keV, Bio-Rad).  Expression of split-GFP fragments was accomplished by first growing cells 
overnight at 250 rpm to saturation at 37 °C in LB supplemented with 100 g/mL ampicillin and 
35 g/mL kanamycin.  Overnight cultures were diluted 1:100 into fresh LB supplemented with 
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100 g/mL ampicillin and 35 g/mL kanamycin.  Cultures were monitored by optical density and 
induced at OD600 = 0.6 using 100 M isopropyl -D-1-thiogalactopyranoside (IPTG) and 0.2% 
(L)-arabinose. Cultures were induced under the appropriate conditions as specified.  
Flow Cytometry Growth and induction was carried out as described above. Flow cytometry 
samples were incubated at a desired temperature and agitated at 250 rpm for the time period 
indicated.  E. coli samples were prepared for flow cytometry by centrifugation (5000 rpm for 5 
minutes) and resuspended in phosphate buffered saline (PBS). All samples were analyzed on a 
MoFlo (Dako Colorado, Inc.) flow cytometer using a solid-state iCyt 488 nm laser. Flow cytometry 
data were analyzed using FloJo software (Tree Star). 
 























































2.10 Primers Used in This Work 
All DNA primers are listed 5' to 3' 
 
NspGFP FP: GGGAATTCCATATGGGTCATCACCACCACCATCACGG 
NspGFP RP: GCGCTCGAGCCAGAGCCAGAGCCACCGCGTTTATCGGCCGTAATATAC 
CscGFP FP: GCAGACGTCGGGTGGAAGCGGTAAGAATGGTATCAAGGC 
CscGFP RP: AGTTGTACATTACTTGTAGCGTTCGTCGCGTCCGTGCTTAATG 
Prb FP: CTGGCTCGAGCGGCAGCACCCGTCCGATTGATGGTCTG 
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Prb RP: GCCGGATCCTTACTATTTTTCGCCCAGCAGGCGTTCGTGC 
Pdar FP: CATGCCATGGCAAGCGATCTGGGTAAAAAGCTGC 
Pdar RP: ACCCGACGTCCCTTGCAGGATCTCTGCCAGATCTTCC 
Gankyrin FP: CATGCCATGGAGGGGTGTGTGTCTAACATAATGATC 
Gankyrin RP: CACCCGACGTCCCCATAGAAGCCTCTTCACCTTCTGCTAGTCTC  
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A Resurfaced Shape Complementary Protein That Selectively Binds 









Ankyrin repeats are among the highest populated domains in Nature and play critical roles 
in various disease-relevant cellular processes. These domains almost exclusively participate in 
PPI’s, and mutation or changes in expression level of many ankyrin repeats is directly linked to 
disease, including many cancers. Ankyrin repeats typically bind their targets on the extended 
concave face formed by a repeating helix-turn-helix-loop motif, and the surface area of many 
ankyrin-repeat PPI’s is often much larger than the average of ~1400 Å2 for a PPI (Figure 3.1).1 
While disruption of PPI’s involving ankyrin repeats is a validated therapeutic strategy, doing so is 
a significant challenge, since these assemblies are often stabilized over large, discontinuous 
surfaces, mainly consisting of charged and polar residues. Thus, it should be unsurprising that 
recognition and modulation of ankyrin repeat-containing PPIs is a complex task for small-
molecule reagents (<800 Da), which traditionally bind protein receptors in small, well-defined 
hydrophobic pockets. In an informative example, a fragment-based discovery approach recently 




Gankyrin is a recently described oncoprotein whose overexpression has been directly 
linked to the onset, proliferation, and/or metastasis of a wide range of cancers, including breast3,4, 
liver5, oral6, pancreatic7, and colorectal cancers8, as well as esophageal squamous cell carcinoma.9 
Additionally, gankyrin has also been shown to play a crucial role in Ras-mediated tumorigenesis, 
which is known to initiate ~30% of all cancers.10 Structurally, gankyrin contains seven ankyrin 
repeat units, which generate a relatively featureless and large concave binding face. Gankyrin 
binds to a variety of physiological targets, including cyclin-dependent kinase 4 (CDK4)11, the E3 
ubiquitin ligase MDM212, and the C-terminal S6 ATPase subunit of the 26S proteasome (referred 
to as S6 ATPase throughout).13 In forming a complex with both CDK4 and Rb, gankyrin drives 
phosphorylation of Rb (pRb), which leads to activation of E2F transcription factors.11,14 By binding 
to MDM2, gankyrin regulates MDM2-dependent polyubiquitination of the tumor suppressor p53, 
resulting in downregulation of p53 and suppression of cellular apoptosis.12 Overall, gankyrin 
overexpression leads to decreased genomic stability and the onset of oncogenic cellular 
phenotypes. For these reasons, identifying reagents that can bind to gankyrin and modulate 
gankyrin PPIs is potentially of great therapeutic interest. 
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The only available structural information for a PPI involving gankyrin (colored) is in 
complex with S6 ATPase (gray, Figure 3.1A). Although relatively little is known about the 
biological role of this PPI, the interaction highlights why inhibiting interactions featuring gankyrin 
may be especially challenging. S6 ATPase tightly binds to gankyrin on the concave binding face 
(a detailed quantitative analysis of the gankyrin-S6 ATPase interaction is discussed in chapter 
four), making discontinuous contacts with all seven ankyrin repeat units. As a result, the binding 
interface between gankyrin and S6 ATPase is ~2400 Å2, which is much larger than the average 
PPI surface (~1400 Å2).15 It is therefore unlikely that gankyrin recognition and modulation is 
within the scope of traditional small-molecule reagents.  
 
3.2 Prb as a Shape Complementary Protein Scaffold  
As discussed in detail in chapter one, proteins represent an attractive alternative to small 
molecules for the potent and selective recognition of difficult macromolecular targets, principally 
due to their ability to take on complex, three-dimensional folds. Modern molecular biology tools 
have significantly simplified the process through which one can identify new proteins with novel 
function. Also discussed in chapter one to some length, innovative technologies now exist to allow 
the functional delivery of proteins into the interior of mammalian cells, opening up the possibility 
for the modulation of intracellular targets, such as gankyrin.16–22 Even with these advances, we are 
still largely incapable of designing functional proteins from scratch. Perhaps the most sensible 
solution is thus one of semi-design: start with a stable protein with a privileged function, and apply 
resurfacing to bind a macromolecule of interest.23  
 Baker and coworkers recently used in silico design and in vitro evolution based on shape 
complementarity to generate a potent PPI involving a PH1109-derived protein called Prb (Figu e
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3.1B, light brown) and a synthetic thermostable ankyrin repeat called Pdar (Figu e 3.1B, blue), 
which was discussed in chapter one.24 PH1109 is a bacterial CoA-binding protein from the 
hyperthermophile Pyrococcus horikoshii. In contrast to many structurally characterized ankyrin 
repeat binding proteins, which are generally very large (>50 kDa) and/or unstable, Prb, and 
mutants thereof, are relatively small proteins (~16 kDa) that are thermostable and expresses 
exceptionally well in E. coli. Additionally, the scaffold has proven that it can reliably be mutated 
at the putative ankyrin repeat binding interface without fear of distorting the overall fold. All of 
these are valuable features when considering a scaffold for potentially generating new gankyrin-
binding proteins. 
 The development of the Pdar-Prb complex highlights both the power and current 
limitations of in silico methods, as well as the utility of high-throughput screening and/or 
macromolecular evolution. For example, while in silico design of the complex provided a valuable 
starting point for its optimization, the reported crystal structure of this protein-protein complex is 
significantly different from the intended in silico design. Additionally, highest affinity complexes 
(KDs into the pM regime) were identified through the application of yeast display screening, a 
common method used for macromolecular evolution.24  
Starting with shape complementarity and privileged scaffold resurfacing as design 
principles, we hypothesized that Prb-derived proteins could be generated to selectively recognize 
gankyrin. The amino acid backbone of gankyrin and Pdar align exceptionally well, with a 
backbone root-mean-square deviation (rmsd) value of 0.69 Å over all Pdar residues (Figure 
3.2A). If a Prb-derived protein binds gankyrin in a manner that is similar to the Pdar-Prb complex, 
the binding face residues on the Prb-derived protein would likely engage large regions of gankyrin, 
and therefore might be able to compete with – or inhibit – disease-relevant complexes involving 
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gankyrin. However, residues on the concave binding face and loop regions of Pdar and gankyrin 
are only ~12% sequence homologous (Figure 3.2B). Furthermore, analysis of the binding face on 
Pdar reveal an extensive hydrophobic patch, which facilitates interaction with Prb. In contrast, 
solvent exposed residues on the putative binding face of gankyrin are primarily polar or 
charged, suggesting that extensive resurfacing of Prb may be required to achieve selective and 
potent recognition of gankyrin. These observations indicate that the generation of a novel 
gankyrin-binding protein is a substantial molecular recognition challenge. Evaluation of the Prb-
Pdar complex revealed eight Prb residues that directly engage, or are nearby, the surface of Pd r 
(N83, A85, K86, W88, R89, Y110, P111, and L112, Figure 3.1C). We reasoned that if a binding 
mode similar to that observed in the Pdar-Prb interaction is utilized, mutation of these residues 
might result in new proteins that selectively recognize gankyrin. The remaining question was how 






3.3 Split-spGFP Screening Reveals New Gankyrin-Binding Proteins    
 In chapter two, we discussed the development of a split-spGFP reassembly assay for the 
identification of PPIs in living cells (Figure 3.3).25 Split-spGFP reassembly is faster, more 
efficient, and more robust than previously described split-GFP methods. In contrast to previously 
reported split-GFP systems26–28, we postulated that the enhanced properties of split-spGFP 
reassembly are likely due to a dramatic decrease in aggregation propensity of the individual GFP 
fragments by virtue of their high theoretical net charge.29 Substantially decreasing the number of 
fragments lost to aggregation not only endows the properties described above, it also should 
increase the number of viable library members when employing split-spGFP in a high-throughput 
manner. Furthermore, unlike the majority of the more common high-throughput screening methods 
used by researchers (ie. phage display, yeast display, and mRNA display), which are performed 
either on the outside of cells or in a test tube, split-spGFP reassembly takes place inside of living 
cells. Screening for new PPIs in the context of a complex cellular milieu should aid in identifying 
physiologically-relevant interactions, as well as impart some degree of binding selectivity. For 
these reasons, we determined that split-spGFP, combined with fluorescence-activated cell sorting 
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(FACS), would be the ideal high-throughput screening tool to identify new gankyrin-binding 
proteins. 
Using standard molecular biology techniques, we prepared a DNA library that encodes 
resurfaced Prb with eight randomized binding face residues (shown in Figure 3.1C). This Prb 
library was cloned into a pET plasmid as a C-terminal fusion to NspGFP. We also cloned gankyrin 
into a pBAD plasmid as an N-terminal fusion to CspGFP. These two plasmids were sequentially 
transformed into E. coli, generating a library of ~5 x 109 transformants. Sequencing ~50 library 
plasmids from our library suggested very efficient randomization of the Prb binding face, as we 
did not observe any duplicate sequences in this region. Doubly transformed E. coli were made to 
concomitantly express the NspGFP-Prb library fusion and gankyrin-CspGFP fusion proteins, and 
incubated at 30 °C for 6 hours. After such time, E. coli with the highest levels of GFP (indicating 
interaction-dependent GFP reassembly) were isolated by FACS. The resulting population (~800 
cells) was re-sorted to separate real binders from potential false positives, based on the original 
gate (Figure 3.4A). Following two rounds of screening, we individually re-screened seven 
resurfaced shape complementary proteins, which bind gankyrin in l ving cells (E. coli, Figure 
3.4B). These proteins are herein referred to as Gankyrin Binding Proteins 1-7 (GBP 1-7). While 
all seven of these resurfaced proteins bind gankyrin (as determined by split-spGFP reassembly), 
we focused on the five best performing proteins (GBPs 1, 3, 4, 5, and 7). 
We further characterized binding by a lysate Enzyme-Linked Immunosorbant Assay 
(ELISA), which – in our hands – is more stringent than split-spGFP reassembly. As shown in 
Figure 3.4C, GBP 3, GBP 5 and GBP 7 appear to strongly bind gankyrin, while other GBPs are 
much weaker binders. Importantly, GBP 5 and GBP 7 do not appreciably bind off-target ankyrin 
repeats Pdar (green bars) and Notch-1 (red bars), which exhibit very high structural homology with 
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gankyrin (backbone atom rmsd = 0.69 and 1.27 Å, respectively, Figure 3.5A), but differ 
dramatically with respect to the makeup of amino acids on their concave binding face. Pdar and 
Notch-1 exhibit ~12% and ~9% sequence homology, respectively, with the concave binding face 
of Gankyrin (Figure 3.5B). 
Binding was further confirmed by measuring the amount of GBP that is co-purified with 
His6x-tagged gankyrin from E. coli cell lysate.30 E. coli was induced to co-express His6x-tagged 
gankyrin and untagged GBP 3, 5 or 7 off of a pETDuet plasmid. Cleared cell lysate was incubated 
with Ni-NTA agarose, followed by washing steps and elution of His6x-tagged gankyrin by addition 
of imidazole. Gankyrin, or gankyrin-GBP co-purified complexes were identified by SDS-PAGE 
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and coomassie staining. As seen in Figure 3.4D, appreciable levels of co-purified GBP 5 and GBP 
7 were observed, while essentially no GBP 3 was co-purified with gankyrin, suggesting that GBP 
5 and 7 are the highest affinity GBPs, and warrant further study. The relative absence of other co-
purified cellular proteins further demonstrates the high level of selectivity that is achieved in these 
newly identified PPIs. 
As stated previously, S6 ATPase does not express independently as a soluble protein. The 
gankyrin-S6 ATPase complex is only generated by co-expressing these two proteins frm a single 
pETDuet plasmid.13 In order to determine if GBP 5 or GBP 7 bind gankyrin in the presence of S6 
APTase – or inhibit this physiological interaction – we performed a modified split-spGFP 
experiment. We co-expressed gankyrin-CspGFP and S6 ATPase from pETDuet and NspGFP-GBP 
5 or -GBP 7 from pBAD, in E. coli. Since gankyrin and S6 ATPase assemble when co-expressed, 
we reasoned that gankyrin-GBP interaction-dependent reassembly of the fused spGFP fragments 
would only occur if GBP 5 or GBP 7 bind gankyrin over S6 ATPase, or recognize a region of 
gankryrin that differs from S6 ATPase. We observed virtually identical amounts of gankyrin 
interaction-dependent GFP signal in E. coli that co-express gankyrin-CspGFP / S6 ATPase and 




3.4 Alanine-Scanning Mutagenesis of GBP 5 and GBP 7  
To assess the contribution of each residue on the resurfaced region of GBP 5 and GBP 7, 
we performed pull-down experiments from E. coli cell lysate containing His6x-tagged gankyrin 
and untagged alanine mutants of each GBP. In each pull-down experiment, a single residue that 
was randomized in construction of the protein library was mutated to alanine (with the exception 
of glycine 83 in GBP 5, which we viewed as a minor change unlikely to dramatically alter complex 
stability). Consistent with our ELISA data, gankyrin does not bind appreciable levels of Prb 
(Figure 3.6A, lane 1), but does co-purify with GBP 5 (Figure 3.6A, lane 2). Three mutations to 
the resurfaced region – R85A, N110A and W111A –decreased the amount of co-purified mutant 
GBP to varying levels (Figure 3.6A, lanes 3, 7, and 8, respectively), suggesting these residues are 
particularly critical for gankyrin recognition. For GBP 7, Y83A, I85A and W86A mutations 
resulted in significantly decreased levels of co-purified mutant GBP (Figure 3.6B, lanes 3, 4, and 
5). For GBP 5 and GBP 7, mutations that result in significantly lower levels of co-purification are 
tightly grouped and different, suggesting unique recognition “hot spots” (Figures 3.6C and 3.6D).  
 
3.5 Biophysical Characterization of GBP 5 and GBP 7 
In the majority of our data (split-spGFP reassembly, ELISA, His6x co-purification) GBP 7 
appears to have the highest affinity for gankyrin. We measured the KD b tween gankyrin and GBP 
7 by Isothermal Titration Calorimetry (ITC). This resurfaced shape complementary protein binds 
gankyrin with good affinity (KD ~ 6 µM, Figure 3.7A). The observed change in enthalpy (ΔH) 
and entropy (ΔS) for this binding interaction were -2.78 kcal/mol and 14.6 cal/mol*K, 
respectively. Consistent with our previous data, GBP 5 binds gankryin, but with lower affinity. 
We observed an unsaturated binding isotherm under identical conditions that were used to measure 
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the GBP 7 - gankyrin interaction (data not shown). Since GBP 5 and GBP 7 are derived from a 
protein natively expressed in the hyperthermophile Pyrococcus horikoshii, these proteins are likely 
to be very thermostable, a desired characteristic of protein reagents. We measured the 
thermostability of Prb and resurfaced gankyrin-binding mutants GBP 5 and GBP 7 by Differential 
Scanning Calorimetry (DSC). Impressively, Prb exhibits a very high melting temperature (Tm) of 
91.1 °C. Despite extensive mutagenesis, both resurfaced mutants GBP 5 and GBP 7 retain 




3.6 Conclusion    
In conclusion, limitations to small molecule reagents and drug leads require fundamentally 
new approaches for the recognition of disease-relevant receptors. The size, electrostatic 
complexity, and relatively featureless surfaces associated with many protein-protein interactions 
involving disease-relevant ankyrin repeat domains present a particularly difficult challenge for 
small molecule reagents. Synthetic proteins offer a unique opportunity to recognize – and
potentially modulate the activity of – challenging macromolecular targets such as ankyrin repeats. 
Here, we described novel synthetic proteins that selectively and tightly bind the oncoprotein 
ankyrin repeat gankyrin. Split-spGFP reassembly, ELISA, and cell lysate pull-down experiments 
suggest that these interactions occur in living cells and are highly selective. These new gankyrin-
binding proteins are thermostable, express well in E. coli as soluble proteins, and represent the 
first synthetic proteins that recognize gankyrin in vitro and in complex cellular environments. 





























Prb (Tm= 91.1 °C) 
GBP 7 (Tm= 87.1 °C) 
GBP 5 (Tm= 86.8 °C) 
A. B.
Figure 3.7 (A) Isothermal titration calorimetry (ITC) binding isotherm for gankyrin and GBP 7. (B)
Differential scanning calorimetry (DSC) for ankyrin repeat-binding proteins Prb (black), GBP 7 (red),
and GBP 5 (blue).
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These proteins likely represent valuable starting points for further optimizing affinity to gankyrin, 
and modulating gankyrin-dependent oncogenic cell function and fate. Efforts toward this end are 
discussed in chapter five. 
 
3.7 Methods 
Library Preparation Plasmids containing Pdar and Prb were generously provided by Professor 
David Baker (University of Washington). The construct NspGFP-Prb was amplified using 
oligonucleotides (all primers purchased from Integrated DNA Technologies, IDT), digested with 
restriction enzymes NcoI and PacI, and ligated into pre-cut pETDuet vector to serve as the 
backbone for the library (all cloning enzymes purchased from New England Biolabs, NEB).
NspGFP-Prb pETDuet was cut with restriction enzymes AatII and BglII for library insertion, 
resulting in 20 µg digested plasmid. The library insert was amplified using the saturation 
mutagenesis primers NNK (and complementary MNN), where N represents a 25% mix each of 
adenine, thymine, guanine, and cytosine nucleotides; and K represents a 50% mix each of thymine 
and guanine nucleotides, and M represents a 50% mix each of adenine and cytosine. NNK codons 
were used to remove 2 of 3 possible stop codons, while maintaining all 20 amino acids. The library 
insert was cut with AatII and BglII and ligated into pre-cut NspGFP-Prb pETDuet plasmid in its 
entirety, resulting in ~12 µg library plasmid DNA, which was subsequently purified via two rounds 
phenol/chloroform extraction and ethanol precipitation. The entire library was transformed in 48 
batches by electroporation into 2.4 ml of electrocompetent 10 s (NEB) using 1mm cuvettes at 1.7 
keV. Cells were allowed to recover in 1L pre-warmed SOC for 1hr. Library size was calculated by 
serial dilution, resulting in a library of ~5.0x109. Carbenicillin was added to a working 
concentration of 100 µg/mL and culture was grown overnight at 37 ºC. Library plasmid DNA was 
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recovered the following day using a maxiprep kit (OMEGA). Gankyrin-CspGFP pBAD was 
prepared by amplifying gankyrin with oligonucleotides, digested with NcoI and AatII, and ligated 
into pre-cut pBAD containing the link-CspGFP construct. 
 
Preparation of Electrocompetent E. coli The gankyrin-CspGFP pBAD construct was 
transformed into chemically competent BL21-Gold (DE3). Cells were made electrocompetent 
following standard procedures. Efficiencies of > 4.0x108 cfu/µg DNA were achieved regularly 
using ~250 ng library DNA.  
 
Fluorescence Activated Cell Sorting (FACS) 2 µg library DNA was transformed by electroporation 
into 400 µl BL21-Gold E. coli containting the gankyrin-CspGFP pBAD construct in 8 batches. 
Cells were rescued in 250 ml pre-warmed 2XYT and allowed to recover for 1hr at 37ºC. 
Kanamycin (50 µg/mL) and carbenicillin were added to the culture and grown until an OD600 of 
0.5 was reached. Cells were brought to room temperature and induced with 0.2% arabinose and 1 
mM isopropyl -D-1-thiogalactopyranoside (IPTG). Growth was continued for 6 hours at 30 °C, 
then cells were pelleted and washed with ice-cold PBS 3x and resuspended in PBS. Cells were 
sorted by FACS using a MoFlo Flow Cytometer and High Speed Cell Sorter with a solid state iCyt 
488nm laser (CSU proteomics) at a rate of 9-11,000 events/second using single sort mode for  5 
hours, setting the GFP-positive gate above the negative control (uninduced). ~800 GFP-positive 
cells were sorted into fresh 2XYT and allowed to recover for 12 hours at 37 °C before the addition 
of antibiotics, and growth was continued overnight. Cells were inoculated into fresh 2XYT 
containing antibiotics and induced (as described above) when OD600 reached 0.5. Growth was 
continued for 6 hours at 30 °C, then prepared for FACS as described above. Cells were sorted a 
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2nd time at a rate of ~5,000 events/second for 30 minutes, taking the top 10% of the GFP-positive 
population. Cells were rescued and grown as described above. Plasmid DNA was harvested the 
following day using a miniprep kit (OMEGA).  
 
Identification of Library Members Plasmid DNA from the 2nd round sort was used as a template 
for a PCR. Prb mutants were amplified, digested with XhoI and PacI, and ligated back into a pre-
cut pETDuet vector containing NspGFP. After transformation into chemically competent 5s, 
individual colonies were picked, cultured, plasmid purified, and sequenced (GENEWIZ). Unique 
sequences were termed Gankyrin Binding Protein (GBP) 1-7 and separately transformed into 
BL21-Gold E. coli containing gankyrin-CspGFP pBAD via electroporation. Each unique GBP was 
verified for binding with split-spGFP reassembly.  
 
Protein Purification Constructs were cloned into pETDuet using restriction enzymes BamHI and 
PacI, resulting in N-terminally His6x tagged proteins and transformed into BL21s (DE3). Cells 
were grown in 2 L LB cultures containing carbenicillin at 37 °C to OD600 = 0.5 and induced with 
1 mM IPTG at 25 °C overnight. Cells were then collected by centrifugation (5000 rpm, 10 
minutes), resuspended in phosphate buffer (20 mM Sodium Phosphate pH 7.4, 150 mM NaCl, 2.5 
mM 2-mercaptoethanol) and stored at -20 °C. Frozen pellets were thawed and sonicated for 2 
minutes. The lysate was cleared by centrifugation (15000 rpm, 30 minutes) and the supernatant 
was mixed with 1 mL of Ni-NTA agarose resin for 1 hour at 4 °C. The resin was collected by 
centrifugation (5000 rpm, 5 minutes). The resin was washed with 50 mL of buffer and 20 mM 
imidazole. The protein was then eluted with 5 mL of buffer containing 400 mM imidazole. The 
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proteins were dialyzed against buffer and analyzed for purity by SDS-PAGE. Purified proteins 
were quantified using absorbance at 280 nm. 
 
ELISA Separately, gankyrin, Pdar, and the Notch-1 ankyrin repeat domain were cloned into 
MCS2 of pETDuet with FLAG tags using restriction enzymes NdeI and PacI. Prb and GBPs were 
cloned into MCS1 of pETDuet using restriction enzymes BamHI and HindIII, resulting in N-
terminal His6x-tagged proteins. Completed constructs were transformed into BL21s (DE3). Cells 
containing the co-expressed pair were inoculated and induced as described previously. Cells were 
spun down (5000 rpm, 10 minutes) and resuspended in lysis buffer (100 mM potassium glutamate, 
20 mM Hepes pH 7.5), lysed by sonication, and spun down (15000 rpm, 20 minutes) to r move 
cell debris. Cleared lysates were incubated on clear Ni-NTA coated plates for 1 hour at r om 
temperature and washed 3x with 200 µL wash buffer (100 mM potassium glutamate, 20 mM Hepes 
pH 7.5, 0.05% Tween-20, 0.01 mg/mL BSA). Horseradish peroxidase (HRP)-conjugated mouse 
anti-DDDDK antibody in LiCor Blocking Buffer was incubated for 1 hour at room temperature 
(1:5000), followed by 4x 200 µL washes. Colorimetry was developed using TMB-One substrate 
and absorbance was measured at 655nm on a plate reader (BioTek).  
 
Lysate Ni-NTA Pull-down Assay Ankyrin repeats (gankyrin and Pdar) were cloned into MCS 1 
of pETDuet using restriction enzymes BamHI and HindII, resulting in N-terminal His6x-tagged 
proteins. Prb and GBPs were cloned into MCS2 of pETDuet using the restriction enzymes NdeI 
and PacI. Completed constructs were transformed into BL21s (DE3). Cells containing the co-
expressed pair were inoculated and induced as described previously. Cells were spun down (5000 
rpm, 10 minutes) and resuspended in lysis buffer (100 mM potassium glutamate, 20 mM Hepes 
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pH 7.5), lysed by sonication, and spun down (15000 rpm, 20 minutes) to remove cell debris. 
Cleared lysate was incubated with 100 µL Ni-NTA agarose resin for 1 hour. Ni-NTA agarose was 
washed with 5 mL lysis buffer and 5 mL lysis buffer with 20 mM imidazole. Proteins were eluted 
with lysis buffer containing 400 mM imidazole. The pull-down was analyzed by SDS-PAGE. 
 
Isothermal Titration Calorimetry (ITC) ITC experiments were performed in collaboration with 
GE Healthcare using a MicroCal iTC200 calorimeter maintained at 25 °C. All proteins were 
purified as described previously and dialyzed extensively in phosphate buffer (20 mM sodium 
phosphate pH 7.4, 150 mM NaCl, 2.5 mM 2-mercaptoethanol). Gankyrin was placed in the sample 
cell at a concentration of 20 µM, and 200 µM of GBP 5 or GBP 7 were titrated in 2 µL increme ts 
(16 injections total) at 160 sec intervals using a stirring speed of 750 rpm. Data were analyzed 
using Origin7.0 (MicroCal, iTC200) using a one set of sites binding model for fitting. 
 
Differential Scanning Calorimetry (DSC) DSC experiments were performed in collaboration 
with GE Healthcare using a MicroCal VP-Capillary DSC system. All proteins were purified as 
described previously and dialyzed extensively in phosphate buffer (20 mM sodium phosphate pH 
7.4, 150 mM NaCl, 2.5 mM 2-mercaptoethanol). DSC experiments were performed using 1 
mg/mL of Prb, GBP 5, and GBP 7 in phosphate buffer containing 2-mercaptoethanol. Temperature 
scanning was performed from 20 to 95 °C at a scan rate of 60 °C/hr using passive feedback mode.  
 





































3.9 Primers Used in This Work 
All DNA primers are listed 5' to 3' 
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Prb Library FP: 
CGGATAAAATTGAGGTCGTAGATCTGTTTGTGNNKCCGNNKNNKGCGNNKNNK 
TTCGTTGTCTATGCCATCAAGAAAGGG 
Prb Library RP: 
TTCCTTGGCTTGACGTCCAGCMNNMNNMNNATATGTGTTGTACTGAAA 
CCATACCACTTTTGC 




Pdar FP: ATATACCATGGCAAGCGATCTGGGTAAAAAGCTGCTG 
Pdar RP: CCTTAATTAATTACCCTTGCAGGATCTCTGCCAGATCTTCC 
Notch-1 FP: CATGCCATGGACGTAAATGTCCGCGGG 
Notch-1 RP: ATATAGACGTCCTCGAGGTCCAGCAGCCT 
Prb FP (includes GBPs): CGCGGATCCGGGCAGCACCCGTCCGATT 
Prb RP (includes GBPs): CCTTAATTAATTATTTTTCGCCCAGCAGGCGTTC 
 
GBP 5 Alanine-Scanning Primers  
R85A FP: GATCTGTTTGTGGGTCCGGCGAGTGCGAAGAATTTCG 
R85A RP: CGAAATTCTTCGCACTCGCCGGACCCACAAACAGATC 
S86A FP: GATCTGTTTGTGGGTCCGAGGGCTGCGAAGAATTTCG 
S86A RP: CGAAATTCTTCGCAGCCCTCGGACCCACAAACAGATC 
K88A FP: GTTTGTGGGTCCGAGGAGTGCGGCGAATTTCGTTGTCTATGC 
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K88A RP: GCATAGACAACGAAATTCGCCGCACTCCTCGGACCCACAAAC 
N89A FP: GTTTGTGGGTCCGAGGAGTGCGAAGGCTTTCGTTGTCTATGC 
N89A RP: GCATAGACAACGAAAGCCTTCGCACTCCTCGGACCCACAAAC 
N110A FP: GGTATGGTTTCAGTACAACACATATGCTTGGTTGGCTGGACGTCAAGCC 
N110A RP: GGCTTGACGTCCAGCCAACCAAGCATATGTGTTGTACTGAAACCATACC 
W111A FP: GGTATGGTTTCAGTACAACACATATAATGCGTTGGCTGGACGTCAAGCC 
W111A RP: GGCTTGACGTCCAGCCAACGCATTATATGTGTTGTACTGAAACCATACC 
 
GBP 7 Alanine-Scanning Primers 
Y83A FP: GAGGTCGTAGATCTGTTTGTGGCTCCGATTTGGGCGACGGAG 
Y83A RP: CTCCGTCGCCCAAATCGGAGCCACAAACAGATCTACGACCTC 
I85A FP: GATCTGTTTGTGTATCCGGCTTGGGCGACGGAGTTCG 
I85A RP: CGAACTCCGTCGCCCAAGCCGGATACACAAACAGATC 
W86A FP: GATCTGTTTGTGTATCCGATTGCGGCGACGGAGTTC 
W86A RP: GAACTCCGTCGCCGCAATCGGATACACAAACAGATC 
T88A FP: GTTTGTGTATCCGATTTGGGCGGCGGAGTTCGTTGTCTATGCC 
T88A RP: GGCATAGACAACGAACTCCGCCGCCCAAATCGGATACACAAAC 
E89A FP: GTATCCGATTTGGGCGACGGCGTTCGTTGTCTATGCC 
E89A RP: GGCATAGACAACGAACGCCGTCGCCCAAATCGGATAC 
H110A FP: GTTTCAGTACAACACATATGCTGGGGAGGCTGGACGTCAAG 
H110A RP: CTTGACGTCCAGCCTCCCCAGCATATGTGTTGTACTGAAAC 
E112A FP: GTACAACACATATCATGGGGCGGCTGGACGTCAAGCCAAGG 
E112A RP: CCTTGGCTTGACGTCCAGCCGCCCCATGATATGTGTTGTAC 
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Characterization of the Binding Interaction Between the 








 In this work, I designed the FtsH-S6 ATPase grafting strategies, as well as carried out 
cloning and protein purification. I also carried out the design, execution, and analysis of isothermal 
titration calorimetry (ITC) experiments. Bryce Rogers, a first year graduate student, made 
contributions to the cloning, purification, and analysis of proteins used in this work, including 





 As discussed in chapter three, overexpression of gankyrin is directly linked to the onset, 
proliferation, and/or metastasis of a large number of cancers.1–7 After identifying GBP 7 (discussed 
in chapter three), which binds gankyrin well (KD ~6 M), we next sought to better understand the 
dictates of gankyrin-binding, as well as be able to potentially quantitatively compare our protein 
to known physiological gankyrin-binding partners. Gankyrin is reported to bind both cyclin-
dependent kinase 4 (CDK4)8 and MDM29, resulting in increased efficiency of pRb 
phosphorylation and p53 polyubiquitination and degradation, respectively. However, the structural 
basis for these interactions has not yet been reported, and neither the targets nor their putative 
gankyrin-binding domains express as soluble recombinant proteins in E. coli (Figure 4.1). A more 
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promising venue for studying gankyrin–protein interactions is the co-crystal structure with a C-
terminal portion of the S6 ATPase from the 26S proteasome, reported by Yokoyama and coworkers 
(Figure 4.2A).10 Preliminary characterization of the recognition interface by Yokoyama and 
coworkers was achieved by a series of pull-down experiments with gankyrin-His6x and S6 ATPase 
mutants (concomitantly expressed from a pETDuet plasmid), in which binding face residues 
believed to participate in complex stability were mutated to mostly alanine (R342A, 
R338A/R342A, R338A/R339A/R342A, E356A/E357A, D359A/D362A, and K397E in S6 
ATPase and R41A, K116A, D39A/D71A, R41A/K116A, and E182A in gankyrin, highlighted in 
Figure 4.2B.  
Efforts to directly probe the gankyrin–S6 ATPase complex are hampered by the tendency 
of the latter to form inclusion bodies when expressed in the absence of gankyrin. In our hands such 
material could not be refolded, and fusion to proteins commonly used to improve stability and 
solubility was likewise ineffective (Figure 4.1). An alternative strategy for display of folded and 
functional S6 ATPase is protein grafting. In this approach, a protein scaffold is identified that is 
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stable, expresses well in E. coli, and contains a domain with excellent structural homology to S6 
ATPase. If that protein is stable enough to tolerate replacement of the structurally homologous 
domain with S6 ATPase, it could serve as a generic platform for display of a folded and functional 
variant of this otherwise inaccessible protein. 
 
4.2 Grafting FtsH-S6 ATPase Results in a Soluble, Folded Protein 
 Our initial efforts to identify such a scaffold relied on the recognition by Yokoyama and 
coworkers that, while the C-terminal portion of FtsH from E. coli has low sequence homology 
(~25%) with S6 ATPase, the two proteins have similar tertiary structures (rmsd of ~1.4 Å over 74 
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main chain residues, Figure 4.2C). Expanding on this finding, we set out to determine if a grafted 
protein–in which the C-terminal ATPase domain of FtsH is replaced with S6 ATPase–expresses as 
a soluble protein in E. coli that mimics the native S6 ATPase/gankyrin interaction. To design the 
grafted protein, S6 ATPase was genetically fused to FtsH, starting after FtsH position 326 and 
beginning with S6 ATPase position 338. The resulting protein is referred to as FtsH-S6 ATPase 
throughout.  
 To our satisfaction, grafted FtsH-S6 ATPase was expressed in E. coli as soluble protein, 
compared to insoluble S6 ATPase (Supplemental Data, Figure S4.1). Additionally, FtsH-S6 
ATPase expressed and purified as a His6x-tagged protein in a comparable yield and purity to the 
wild-type FtsH (wt-FtsH, Supplemental Data, Figure S4.2).  Circular dichroism (CD) spectra of 
the two proteins show they are virtually identical (Figure 4.3A), suggesting no appreciable 
structural change to the FtsH scaffold or grafted S6 ATPase domain. 
 
4.3 Alanine-Scanning Mutagenesis Reveals FtsH-S6 ATPase Faithfully Mimics S6 ATPase 
Binding 
 Affinity of this grafted protein to gankyrin was first assessed using a pull-down assay in E. coli. 
Binding face residues on gankyrin or FtsH-S6 ATPase were mutated to alanine (based on the 
findings of Yokoyama and coworkers using S6 ATPase), and their effect on complex stability was 
qualitatively assessed by measuring the amount of untagged FtsH-S6 ATPase co-purified with 
gankyrin-His6x. Most notably, FtsH-S6 ATPase R338A/R339A/R342A (Figure 4.3B, lane 4), 
FtsH-S6 ATPase D359A/D362A (Figure 4.3B, lane 6), gankyrin R41A (Figure 4.3C, lane 2), 
gankyrin R41A/K116A (Figure 4.3C, lane 4), and gankyrin D39A/D71A (Figure 4.3C, lane 5) 
appear to form significantly less stable complexes than the native proteins. This is in contrast to 
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Yokoyama’s original pull-down, in which all mutants but R342A S6 ATPase did not appreciably 
co-purify with gankyrin-His6x. This highlights a potential virtue of our grafting approach. It is 
unclear if mutations to this unstable form of S6 ATPase appreciably modulate, or abolish, 
gankyrin/S6 ATPase complex stability, or simply further decrease structure and stability of the C-
terminal S6 ATPase fragment.  
 
4.4 Characterizing the FtsH-S6 ATPase-Gankyrin Interaction by ITC 
 While the FtsH scaffold displays S6 ATPase in a manner that faithfully mimics the native protein 
(facilitates binding to gankyrin), no information on the exact differences in binding energies can 
be obtained using the pull-down assay. Moreover, mutational effects that do not dramatically 
lower, or completely abolish, complex stability cannot be probed using this assay. Only through 
the described grafting strategy are able to create a soluble and stable mimic of S6 ATPase, which 
permits the use of more sensitive biophysical methods to probe this important binding interaction. 
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 We used Isothermal Titration Calorimetry (ITC) to obtain the full thermodynamic signature 
(ΔH, –TΔS, ΔG) and stoichiometry (N-value) of this interaction, as well as characterize mutational 
effects on complex stability. Perhaps not surprising, we found that gankyrin binds the grafted FtsH-
S6 ATPase with a dissociation constant (KD) of ~ 67 nM (Table 4.1, entry 1).  The observed change 
in enthalpy (ΔH) and entropy (-TΔS) for this binding interaction were –28.7 kcal/mol and 19.0 
kcal/mol, respectively. Gankyrin does not bind wt-FtsH with any appreciable affinity 
(Supplemental Data, Figure S4.3), which is unsurprising, given that the S6 and FtsH ATPase 
subdomains share only ~25% sequence homology. These results confirmed our prediction that 
gankyrin and S6 ATPase form a high affinity complex, due to the fact that S6 ATPase makes contact 
with all seven repeating ankyrin units of gankyrin. 
 Alanine mutation of S6 ATPase R342, which engages gankyrin through a salt bridge with 
gankyrin E182, modestly lowers complex stability (KD = 216.6±25.8 nM, Table 4.1, entry 2). 
Double (R338A/R342A) and triple (R338A/R339A/R342A) mutation of a positively charged 
patch on the S6 ATPase face, which disrupts a salt bridge between S6ATPase R342 and gankyrin 
E182, dramatically lower complex stability (KD = 2.5±0.4 µM and 7.5±0.2 µM, Table 4.1, entries 
3 and 4, respectively). Interestingly, both of these mutations result in favorable binding entropy (-
TΔS = -1.5±0.8 and -4.7±0.1 kcal/mol, respectively, compared to -TΔS = 19.0±0.6 for the native 
interaction). While the molecular mechanism for this dramatic change is unclear, one possible 
rationale is a lower energy of desolvation for the alanine mutants, compared to the native protein. 
While Yokoyama’s original pull-down data suggest a significant role for S6 ATPase E356/E357 in 
complex stability, double alanine mutation did not appreciably lower binding affinity (Table 4.1, 
entry 5). Conversely, removal of a negatively charged patch on the S6 ATPase binding face 
(D359A/362A, Table 4.1, entry 6) completely abolished binding. An E182A mutation in 
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gankyrin—which further probes a salt brigde with S6 ATPase 342—was found to modestly lower 
bindng affinity (KD = 140.6±9.7 nM, Table 4.1, entry 12), further suggesting a relatively minor 
role of this interaction in complex stability. Residue K397 in S6 ATPase makes a salt bridge with 
gankyrin D39/D71. However, a mutant that reverses the ionic nature of this residue (K397E) binds 
gankyrin with a similar affinity to the native protein (KD = 95.2±12.2 nM, Table 4.1, entry 7), 
suggesting a relatively minor role of this particular salt bridge in complex stability. While gankyrin 
mutations K116A and D39A/D71A mutations had minimal effects on binding affinity (Table 4.1, 
entries 9 and 10, respectively), an R41A mutation significantly decreased affinity (KD = 
313.3±17.6 nM, Table 4.1, entry 8). While the single K116A mutation had a minimal effect on 
binding, an R41A/K116A double mutation—which is designed to test the role of a larger hydrogen 
bond / salt-bridge network—dramatically lowers affinity  (KD = 3.6±0.4 µM, Table 4.1, entry 11). 
The R41A/K116A mutant, however, binds gankrin with a favorable binding entropy (-TΔS = -
2.5±0.7 kcal/mol), possibly due to a lower energy of desolvation for the alanine mutants, compared 
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to the native protein. The binding stoichiometry (N) for each interaction was found to be ~1 (N = 
0.91-1.02, Supplemental Data, Table S4.1).  
 
 4.5 Conclusion 
 Collectively, our findings represent the first quantitative assessment of the binding interaction—
and binding thermodynamics—of a physiologically-relevant complex involving the oncoprotein 
gankyrin. These data also potentially establish a target affinity for therapeutic reagents designed 
to inhibit gankyrin-dependent protein-protein interactions11, including any gankyrin-binding 
protein variants12, as well as a tool for assessing competitive binding. FtsH-S6 ATPase’s value as 
a comparative tool is discussed further in chapter five. 
 
 4.6 Methods 
Protein Purification Grafted FtsH-S6 ATPase was overlapped and amplified by PCR using 
oligonucleotides (all primers purchased from Integrated DNA Technologies, IDT), and cloned into 
a pET plasmid using restriction enzymes BamHI and PacI, resulting in a N-terminally His6x tagged 
construct (all cloning enzymes purchased from New England Biolabs, NEB), which was confirmed 
by DNA sequencing (all constructs in this manuscript were confirmed by GENEWIZ, South 
Plainfield, NJ). FtsH-S6 ATPase mutants were made using site-directed mutagenesis. These 
constructs were transformed into BL21s (DE3). Gankyrin was cloned into a pET plasmid using 
restriction enzymes NcoI and PacI, resulting in a C-terminally His6x tagged construct, and 
transformed into BL21s (DE3). Gankyrin mutants were made using site-directed mutagenesis, and 
transformed into BL21s (DE3). Cells were grown in 1-2.5 L LB cultures containing 100 g/mL 
carbenicillin at 37 °C to OD600 = ~0.6 and induced with 1 mM isopropyl -D-1-
81 
 
thiogalactopyranoside (IPTG) at 25 °C for 8 hours. Cells were then collected by centrifugation, 
resuspended in phosphate buffer (20 mM sodium phosphate pH 7.4, 150 mM NaCl) with protease 
inhibitor tablets (Roche) and stored at -20 °C. Frozen pellets were thawed and sonicated (Branson) 
for 2 minutes. The lysate was cleared by centrifugation (15000 rpm, 30 minutes) and the 
supernatant was mixed with 1 mL of Ni-NTA agarose resin for 1 hour. The resin was collected by 
centrifugation (5000 rpm, 5 minutes). The resin was washed with 50 mL of buffer containing 20 
mM imidazole, followed by 10 mL with 50 mM imidazole. The protein was then eluted with 5 mL 
buffer containing 400 mM imidazole. The proteins were dialyzed against phosphate buffer and 
analyzed for purity by SDS-PAGE and coomassie staining. Purified proteins were quantified using 
absorbance at 280nm and confirmed with a modified Lowry Assay. 
 
Lysate Ni-NTA Pulldown Assay Gankyrin variants were cloned into MCS1 of pETDuet using 
restriction enzymes BamHI and HindIII, resulting in N-terminal His6x-tagged constructs. FtsH-S6 
ATPase constructs were cloned into MCS2 of pETDuet using the restriction enzymes NdeI and 
PacI. Completed constructs were transformed into BL21s (DE3). Cells containing the co-expressed 
pair were inoculated and induced as described previously. Cells were spun down and resuspended 
in lysis buffer (20 mM sodium phosphate pH 7.4, 150 mM NaCl, 1 mM DTT) lysed by sonication, 
and spun down to remove cell debris. Cleared lysate was incubated with 100 L Ni-NTA agarose 
resin for 1 hour at 4 °C. Ni-NTA agarose was washed with 5mL lysis buffer and 5mL lysis buffer 
with 20 mM imidazole. Proteins were eluted with lysis buffer containing 400 mM imidazole. The 




Isothermal Titration Calorimetry Isothermal titration calorimetry was performed using a 
MicroCal iTC200 calorimeter maintained at 25 °C. All proteins were purified as described 
previously and dialyzed extensively in phosphate buffer (20 mM sodium phosphate pH 7.4, 150 
mM NaCl, 2.5 mM 2-mercaptoethanol). FtsH-S6 ATPase variants were placed in the sample cell 
at concentrations ranging from 15-18 M (30 M for FtsH-S6 ATPase R338A/R339A/R342A), 
and 150-180 M (500 M for FtsH-S6 ATPase R338A/R339A/R342A interaction) of gankyrin 
variants were titrated in 2.49 L increments (16 injections total), with an initial injection of 0.2 
L, at 180 second intervals using a stirring speed of 750 rpm. Heats of dilution were measured in 
the same manner described above, separately titrating buffer into buffer and gankyrin into buffer. 
Data were analyzed using Origin7.0 (MicroCal, iTC200) using a one set of sites binding model for 
fitting. All data were reference subtracted by subtracting the mean heat of dilution from each data 
point. Al l data were performed in triplicate  
 
Circular Dichroism Proteins were purified as described above. Separately, each protein was 
diluted to 5 M in phosphate buffer (20 mM sodium phosphate pH 7.4, 150 mM NaCl, 2.5 mM 2-
mercaptoethanol) and placed in a quartz cuvette with a pathlength of 0.2 cm. Data were collected 
on an Aviv model 202 circular dichroism spectrometer. Wavelength data were taken from scans 
of 250 nm to 200 nm in 1 nm steps at 25 °C.  
 





























































































4.8 Primers Used in This Work 
All DNA primers are listed 5' to 3' 
 
















































FtsH-S6 ATPase mutant primers 
R342A FP: CCGGACCGCCGCGGGAAGGCACAGATTTTCTCCACTCAC 









E356A/E357A FP: GCAAGATGAACCTCTCTGCGGCGGTTGACTTGGAAGACTATG 
E356A/E357A RP: CATAGTCTTCCAAGTCAACCGCCGCAGAGAGGTTCATCTTGC 
D359A/D362A FP: CCTCTCTGAGGAGGTTGCCTTGGAAGCCTATGTGGCCCGGCCAG 
D359A/D362A RP: CTGGCCGGGCCACATAGGCTTCCAAGGCAACCTCCTCAGAGAGG 
K397E FP: CTACATTGTCCTGGCCGAGGACTTCGAGAAAGC 
K397E RP: GCTTTCTCGAAGTCCTCGGCCAGGACAATGTAG 
 
Gankyrin mutant primers 
R41A FP: CTAGAACTGATCAGGACAGCGCAACAGCTTTGCACTGGGCATG 
R41A RP: CATGCCCAGTGCAAAGCTGTTGCGCTGTCCTGATCAGTTCTAG 
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K116A FP: CACTCCATTATGCAGCTTCGGCGAATAGGCATGAGATTGCTG 
K116A RP: CAGCAATCTCATGCCTATTCGCCGAAGCTGCATAATGGAGTG 
D39A FP: GCTACTAGAACTGATCAGGCCAGCAGAACAGCTTTGCAC 
D39A RP: GTGCAAAGCTGTTCTGCTGGCCTGATCAGTTCTAGTAGC 
D71A FP: GCCAGTGAATGATAAAGATGCCGCAGGTTGGTCTCCTCTTC 
D71A RP: GAAGAGGAGACCAACCTGCGGCATCTTTATCATTCACTGGC 
E182A FP: CACTTAGCCTGTGATGCAGAGAGAGTGGAAGAG 
E182A RP: CTCTTCCACTCTCTCTGCATCACAGGCTAAGTG 
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A Synthetic Protein that Potently and Selectively Binds the 
Oncoprotein Gankyrin, Disrupts Its Interaction with S6 ATPase, 









In chapter three of this thesis, we described the use of an ankyrin repeat shape-
complementary protein (Prb, Figure 5.1A, tan) as a scaffold for developing new gankyrin-binding 
proteins.  Prb binds Pdar (Figure 5.1A, blue), an in silico designed thermostable ankyrin repeat 
with a largely hydrophobic binding face.1 We randomized eight residues on the ankyrin repeat 
shape-complementary surface of Prb (Figure 5.1B) to all possible proteinaceous amino acids using 
standard molecular biology methods. We then performed two-rounds of split-superpositive GFP 
reassembly, and in cellulo screen we recently reported (chapter two)2, to identify new proteins that 
bind gankyrin in a complex cellular environment (E. coli cells). The best protein we identified 
(GBP7, Figure 5.1B) binds gankyrin with moderate affinity (KD ~6 M). This work highlighted 
the utility of using protein shape complementarity as a starting design principle towards targeting 
ankyrin-repeat proteins.   
Overexpression of the ankyrin repeat oncoprotein gankyrin (Figure 5.2A, orange) is 
directly linked to the onset, proliferation, and/or metastasis of many cancers, including breast3,4, 
liver5, oral6, pancreatic7, and colorectal cancers8. Additionally, gankyrin plays a prominent role in 
Ras-initiated tumorigenesis, which is operative in ~30% of all cancers9. Consistent with most 
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ankyrin repeat proteins10, gankyrin does not have enzymatic activity. Disease-relevant processes 
originate from higher than normal cellular levels of gankyrin, resulting in abnormally high levels 
of protein-protein interactions (PPI’s) involving this oncoprotein. For example, in cells that 
overexpress gankyrin, cyclin-dependent kinase 4 (CDK4) is bound by gankyrin at abnormally high 
levels. Through mechanisms that are not well understood, CDK4/gankyrin assembly increases the 
extent to which CDK4 phosphorylates retinoblastoma protein (Rb).11,12 Increased cellular levels 
of phosphorylated Rb (pRb) leads to over-activation of E2F transcription factors and aberrant E2F-
dependent transcription (Figure 5.2B).11 Additionally, gankyrin can bind to the E3 ubiquitin ligase  
murine double minute 2 (MDM2), and in doing so, increases the extent to which p53 is 
ubiquitinated/polyubiquitinated (Figure 5.2C).13,14 Increased ubiquitination/polybuiquitination of 
p53 by the MDM2/gankyrin complex ultimately leads to p53 degradation in the proteasome and 
suppression of p53-dependent apoptosis. Collectively, these gankyrin-dependent processes result 
in genome instability and cancer. Finally, gankyrin is known to function as a chaperone for the 
formation of the 26S proteasome15, where it also associates with the S6 ATPase sub-unit (referred 
to as S6 ATPase herein, Figure 5.2A, grey).12,16 It is believed that association between gankyrin 
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and S6 ATPase facilitates delivery of polyubiquitinated p53 to the proteasome. Disease-relevant 
cellular processes resulting from increased cellular levels of PPIs that involve gankyrin make 
disruption of these assemblies an attractive therapeutic strategy.17,18  
GBP7 represents the first example, to our knowledge, of a synthetic protein that binds 
gankyrin with good affinity (KD ~6 M).18 However, it is likely that selective disruption of the 
PPIs involving gankyrin described above, as well as modulation of gankyrin-dependent 
oncogenesis, may require more potent recognition (KD <100 nM) of this oncoprotein. Towards this 
goal, we hypothesized that GBP7 could be subjected to additional rounds of so-called ‘affinity 
maturation’ to yield more potent gankyrin-binding proteins. Our initial resurfaced Prb library, 
described in chapter three, focused on mutating (through saturation mutagenesis) 8 residues 
located on the putative ankyrin repeat binding face. Although we performed alanine scanning 
mutagenesis to identify which of these mutated residues were most important for gankyrin-
binding, it is largely unclear how GBP7 contacts gankyrin, and therefore unclear which additional 
positions could be subjected to saturation mutagenesis. In the absence of more detailed structural 
characterization, it would be a somewhat daunting task to continue optimization of this scaffold in 
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a directed manner. With these limitations in mind, random mutagenesis of the entire GBP7 
sequence (by error-prone PCR and DNA shuffling) represents the most attractive strategy for 
affinity maturation. 
 The original Prb resurfaced library was screened against gankyrin using our split-spGFP 
reassembly technology. Split-spGFP was the screening method of choice for the initial Prb library 
screen because it could be performed in cellulo, effectively building in binding-selectivity due to 
the presence of countless other macromolecule species, including other ankyrin repeat proteins. In 
addition, the screening process was relatively quick and simple; two rounds of screening over the 
span of roughly a week resulted in identifying our starting point, GBP7. However, split-spGFP has 
potential limitations when considering its use as a tool for further affinity maturation. Most 
notably, it is still somewhat unclear if there is a direct quantitative link between increased cellular 
GFP fluorescence levels and PPI binding affinity, a limitation that is fairly ubiquitous for in cellulo 
reporter-based protein-fragment complementation assays (PCAs).19,20  
In contrast to PCAs, display-based high-throughput screening tools, including yeast 
display21, phage display22, and mRNA/ribosome display23, have been utilized extensively to 
generate proteins/peptides that potently bind to their desired protein target. mRNA and ribosome 
display are cell-free techniques that can be used to screen remarkably large libraries (>1010), but 
are operationally challenging. Phage display is the most widely used method for molecular 
evolution of proteins/peptides, including evolution of antibody fragments that resulted in FDA-
approved humanized antibodies.24 However, we chose to employ yeast display to screen our GBP7 
random mutagenesis library for several reasons. First, yeast display is an operationally simple 
technique that allows for quantitative screening with the use of two-color labeling fluorescence-
activated cell sorting (FACS, display and binding). Protein target concentration can be controlled 
99 
 
(lowered) over iterative rounds of screening to identify displayed proteins with increasingly tight 
binding affinity. Since fluorescence signal correlates directly with improved fitness, displayed 
proteins can be simultaneously screened for both increased stability (i.e. higher display signal) and 
binding affinity. In addition, PPI affinity can be directly measured using yeast display, eliminating 
the need for additional cloning and characterization steps. Although the potential library size is 
theoretically smaller using yeast display screening than with comparable methods (~107 vs. >109), 
the advantages stated above outweigh this fact when screening a random mutagenesis library.25  
Starting from GBP7, we applied yeast display, error-prone PCR, DNA shuffling, and 
protein engineering to identify new gankyrin-binding proteins with dramatically improved affinity 
(KD ~20 – 100 nM). Isothermal Titration Calorimetry (ITC) was used to provide the 
thermodynamic signature of these interactions, as well as measure the effect mutations in, near, or 
relatively far from the putative gankyrin-binding site have on binding affinity. The highest affinity 
protein binds gankyrin very tightly (KD ~21 nM) and with exquisite selectivity in cell lysate. This 
protein is also able to modulate the PPI between gankyrin and S6 ATPase, and dramatically 
suppress gankyrin/MDM2-dependent polyubiquitination of p53. The proteins described in this 
chapter represent the tightest gankyrin-binding reagents known to date; the highest affinity 
proteins bind gankyrin ~3-fold tighter than S6 ATPase, a physiological binding partner of 
gankyrin. Additionally, these proteins represent the only known protein modulators of gankyrin 
function (p53 ubiquitination). 
 
5.2 Yeast Display Screening Reveals Potent Synthetic GBPs 
We began with GBP7, a synthetic protein we recently reported that binds gankyrin with 
moderate affinity (KD ~6 µM, described in chapter three).18 We performed rounds of yeast display 
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screening21, error-prone PCR26, DNA shuffling27, and protein engineering to optimize this 
interaction. Other than the putative ankyrin repeat binding face, which we previously matured for 
gankyrin affinity by split-superpositive GFP reassembly, it was unclear which residues in GBP7 
should be mutated to improve affinity. Thus, we started by incorporating mutations in an unbiased 
manner using error-prone PCR (ep-PCR), and identified the tightest binders by yeast display. 
Using a commercially available ep-PCR kit (GeneMorph II Random Mutagenesis Kit, Agilent) we 
prepared a library of GBP proteins. Sequencing 30 library members after a single round of ep-PCR 
indicated that approximately four nucleic acid mutations occurred per gene. Following standard 
methods, we performed yeast display to identify proteins with improved affinity. Briefly, a library 
of gankyrin-binding proteins (generated by ep-PCR) was displayed on EBY100 saccharomyces 
cerevisiae. EBY100 constitutively express and display the Aga1 mating protein. GBPs are cloned 
into a pcTCON2 vector as fusions with Aga2, which forms disulfide linkages with Aga1 when 
secreted from the yeast cell. In addition, displayed GBPs contain a C-terminal myc t g. Thus, cells 
can be incubated with a commercially available fluorescein isothiocyanate (FITC)-labelled anti-
myc antibody and display efficiency of folded library members can be measured by flow 
cytometry. The yeast display library was incubated with varied concentrations of gankyrin that 
was first biotinylated with BirA using standard methods28, then complexed with a streptavidin-
phycoerythrin (PE) conjugate. Since the emission profiles of FITC and phycoerythrin are 
orthogonal, relative phycoerythrin:FITC levels can be measured by flow cytometry, and those 
yeast with the highest levels of bound gankyrin were sorted by FACS. Following the first round 
of yeast display and FACS, enriched yeast was grown to confluence over 3 days and plasmid DNA 
was extracted (Yeast Plasmid Miniprep II, Zymoprep). Library DNA was either used in further 
diversification or sequenced. 
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 The library generation and screening protocol to optimize gankyrin-binding affinity and 
selectivity is shown in Figure 5.3A. In yeast display rounds 1-4, library generation was achieved 
by ep-PCR. In each round, the level of gankyrin was decreased (round 1: 1000 nM; round 2: 500 
nM; round 3: 100 nM; round 4: 50 nM, described in Table S5.1) to ensure that only the tightest 
gankyrin-binding proteins were enriched to the next round of screening. In the fifth round, no 
diversification reaction was done; however, we challenged gankyrin-binding proteins by adding 
unlabeled off-target ankyrin repeat proteins. The enriched library of yeast displayed gankyrin-
binding proteins were incubated with 50 nM gankyrin-phycoerythrin and 1 µM each of Pdar, a 
synthetic ankyrin repeat that is bound by the scaffold protein Prb1, and p16INK4a, an ankyrin 
repeat protein that competes with gankyrin for binding to CDK4.11 Thus, any yeast displayed 
protein that bound gankyrin in round 5 selectively did so in the presence of 20 equivalents each of 
unlabeled off-target protein. Flow cytometry data from each round is shown in Figure 5.3B; 
enriched cells are highlighted by encapsulation in the dashed box.  
 Following the first five rounds of yeast display screening, we sequenced ten clones and 
performed an initial assessment of gankyrin-binding by an Enzyme-Linked Immunosorbent Assay 
(ELISA). Briefly, biotinylated gankyrin was immobilized onto streptavidin-coated plates (Pierce). 
Solutions containing 25 nM C-terminally FLAG-tagged GBPs (GBP7.1-GBP7.10) were incubated 
with immobilized gankyrin, then washed 3 times. Following incubation with an anti-FLAG-HRP 
antibody (Abcam), and after subsequent washing steps, TMB-One HRP substrate (Promega) was 
added and relative amounts of complex in each well was measured by colorimetric analysis o  a 
plate reader. As shown in Figure 5.4A, all of the proteins we tested exhibit appreciable affinity 
for gankyrin. However, two of the clones (GBP7.5 and GBP7.7) were the most potent gankyrin-
binding proteins and thus were investigated further. To provide more quantitative feedback on the 
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effectiveness of our yeast display screening, the binding affinity, thermodynamic signature, and 
stoichiometry of these new protein-protein interactions were characterized by ITC. As shown in 
Figure 5.4B, GBP7.5 and GBP7.7 bind gankyrin with significantly improved affinities (KD ~139 
and ~125 nM, respectively), compared to our starting point GBP7 (KD ~6 µM), representing a ~46-
fold improvement in affinity. 
 To further optimize the complex, we performed DNA shuffling on the entire sub-library of 
clones that were enriched in round 5, and screened the shuffled protein library by yeast display. 
We sequenced 25 clones and performed an initial assessment of gankyrin-binding by ELISA. The 
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best performing clones are show in Figure 5.4C. Similar to the previous ELISA experiment, all 
of the proteins exhibited appreciable affinity for gankyrin; however, two of the clones (GBP7.15 
and GBP7.17) were the most potent gankyrin-binding proteins, and thus the complex between 
these proteins and gankyrin was further characterized by ITC. As shown in Figure 5.4D, DNA 
shuffling generated proteins with significantly improved affinity. GBP7.15 and GBP7.17 bind 
gankyrin with low nanomolar dissociation constants (KD ~62 and ~42 nM, respectively): a ~120-
fold improvement from the initial complex involving GBP7. The observed changes in enthalpy 
(ΔH) and entropy (-TΔS) for the PPI involving gankyrin and GBP7.15 were -8.9 (±0.2) and -0.9 
(±0.2) kcal/mol, respectively. The observed changes in enthalpy (ΔH) and entropy (-TΔS) for the 
PPI involving gankyrin and GBP7.17 were -13.5 (±0.5) and 3.5 (±0.5) kcal/mol, respectively. 
 PH1109, the precursor protein to Prb, is a Coenzyme A (CoA)-binding protein.29 Although 
CoA is not involved in the binding interaction between Prb and Pdar, co-crystallization of the 
complex was only achieved in the presence of CoA, suggesting that CoA plays a role in stabilizing 
either Prb, or the complex in general.1 One concern we had when identifying ew GBPs was that 
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CoA, which binds adjacent to the resurfaced region on Prb, might still be able to bind to our 
synthetic proteins and disrupt the gankyrin-GBP interaction in mammalian cells, potentially 
complicating downstream biochemical applications (Figure 5.5A). In order to address this 
concern, we performed a modified ITC experiment with our tightest binding variant, GBP7.17. 
The modified experiment consisted of titrating gankyrin into a 1:1 mix of GBP7.17 and CoA. In 
the presence of CoA, gankyrin still tightly binds to GBP7.17 (KD ~50 nM, Figure 5.5B), 
suggesting that CoA has little, if any, effect on the binding interaction. Additionally, we saw no 
binding isotherm when GBP7.17 was titrated into CoA, suggesting that CoA has no appreciable 
binding affinity for GBP7.17 (Figure 5.5C). 
 
5.3 Mutational Analysis of New GBPs 
Of the 25 clones we sequenced from the enriched gankyrin-binding library, three 
mutations, N55Y (which is near the putative ankyrin repeat binding face), D79G and R132C (both 
relatively distant from the putative ankyrin repeat binding face) were found in all 25 sequenced 
clones (Figure 5.6A and Figure 5.6B, boxed). In order to measure the importance of each mutation 
in gankyrin recognition, we prepared a library of reversion mutants and measured their affinity for 
gankyrin by ITC. Reverting the cysteine at position 132 back to arginine decreased affinity ~2.8-
fold, compared to GBP7.17 (Figure 5.6C). The G79D reversion mutant bound gankyrin with no 
appreciable loss in affinity (Figure 5.6D). Interestingly, mutating tyrosine 55 back to asparagine 
had a much more dramatic effect, and resulted in ~22.5-fold lower affinity for gankyrin (Figure 
5.6E). This makes sense, since residue 55 is relatively close to the putative gankyrin-binding face 
and might directly engage gankyrin.  
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Among the residues that were initially optimized in our previous work to generate the 
starting protein GBP7, one (H110R) was mutated in GBP7.17 as a result of ep-PCR and DNA 
shuffling. Additionally, a Y93C mutation was found near the initially optimized binding face. To 
measure the importance of these residues, we made reversion mutants and measured their affinity 
for gankyrin by ITC. Interestingly, converting cysteine 93 back to tyrosine only lowered affinity 
for gankyrin by ~2.2-fold, compared to GBP7.17 (Figure 5.6F). Additionally, reverting arginine 
110 back to histidine only lowered affinity by ~1.5-fold (Figure 5.6G). 
 
5.4 Optimizing the Gankyrin-GBP PPI 
Three mutations on or near the designated gankyrin-binding face differentiate the two best 
performing GBPs (GBP7.15 and GBP7.17). Both an E112V and Y93H mutation are found in 
GBP7.15, and these residues reside within the originally matured gankyrin-binding face. Slightly 
outside of this, we observe an E57K mutation in GBP7.15. As stated previously, a Y93C mutation 
was found in our best performing GBP (GBP7.19). However, reversion of this residue did not 
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dramatically lower binding, suggesting residue 93 plays a less prominent role in stabilizing a 
complex with between gankyrin and GBP7.17. Given this, we focused on integrating the E112V 
Figure 5.6 (A and B) GBP7.15 and GBP7.17, which were identified as the tightest gankyrin-binding
proteins following screening of the DNA shuffled library. Green colored residues were generated in our
earlier work as a result of split-superpositive GFP screening, and were thus found in the starting protein
(GBP7). Red colored mutations were generated in this work, as a result of error-prone PCR and DNA
shuffling. (C-G) ITC data for five reversion mutants of GBP7.17, which provided information on which
residues are most critical to gankyrin recognition. (H-J) ITC data for GBP7.17 based proteins that
contain mutations found in GBP7.15. Stated KD values are the mean of three independent
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and/or E57K mutations found in GBP7.15 into our best performing protein (GBP7.17), and 
measuring how each change alters affinity for gankyrin. 
Replacing the glutamic acid at position 112 in GBP7.17 with the valine that is found in 
GBP7.15 does not appreciably improve affinity for gankyrin (Figure 5.6H). In contrast, mutating 
the negatively charged glutamic acid at position 57 in GBP7.17 with the positively charged lysine 
that is found in GBP7.15 results in a mutant with significantly improved affinity (KD ~21 nM, 
Figure 5.6I). This protein is referred to as GBP7.19 herein. This is consistent with our earlier 
finding that the Y55N reversion mutation resulted in dramatically lowered affinity for gankyrin. 
Collectively, these two results suggest that the surface of GBP7.19 displaying residues 55 and 57 
might directly engage gankyrin, and as a result, the chemical makeup of these residues can 
dramatically effect complex stability with gankyrin. The observed changes in enthalpy (ΔH) and 
entropy (-TΔS) for the PPI involving gankyrin and GBP7.19 were -13.8 (±0.3) and 3.3 (±0.2) 
kcal/mol, respectively. Addition of the E57K and E112V mutation to the GBP7.17 scaffold does 
not appreciably improve affinity, compared to GBP7.19 (KD ~22 nM, Figure 5.6J). Owing to its 
affinity for gankyrin, we focused on measuring the selectivity of the GBP7.19/gankyrin 
interaction, and the ability of GBP7.19 to modulate a physiologically-relevant gankyrin-dependent 
PPI and a gankyrin-dependent and disease-relevant biochemical process. 
 GBP7.19 binds gankyrin with exquisite selectivity, when expressed in E. coli with His6x-
tagged gankyrin, the two proteins co-elute following nickel-NTA purification (Figure 5.6K, lane 
2). Appreciable levels of other co-purified proteins is not observed, demonstrating the selectivity 





5.5 GBP7.19 Inhibits the Gankyrin/S6 ATPase PPI 
Any therapeutic utility of gankyrin-targeted reagents requires tight and selective 
recognition of this oncoprotein. In this regard, the proteins described above are excellent 
candidates. However, modulation of disease-relevant gankyrin activity likely requires physical 
disruption or inhibition of physiological PPIs. As stated above, gankyrin is known to bind CDK4 
and MDM2, leading to increased Rb phosphorylation and p53 polyubiquitination, respectively. 
Unfortunately, challenges exist when trying to express recombinant CDK4 or MDM2 in E. coli. 
Gankyrin is also known to bind the C-terminal portion of S6 ATPase, a proteasomal subunit 
(Figure 5.1A).  
 As described in chapter four, we recently grafted the C-terminal ATPase subdomain of S6 
onto the C-terminal ATPase subdomain of FtsH, an E. coli derived protein, and showed that this 
new protein (FtsH-S6 ATPase, Figure 5.7A) expresses well in E. coli, is folded in solution, and 
binds gankyrin with excellent affinity (KD ~67 nM, Figure 5.7B). Since FtsH-S6 ATPase 
expresses independent of gankyrin, this surrogate for the C-terminal subunit of S6 ATPase can be 
used to determine if GBP7.19 modulates the gankyrin/S6 ATPase interaction, and physically 
disrupts this complex. 
 The ability of our tightest gankyrin-binding protein (GBP7.19) to modulate the FtsH-S6 
ATPase/gankyrin interaction was initially tested by ITC. As stated above, FtsH-S6 ATPase binds 
gankyrin with excellent affinity (KD ~67 nM, Figure 5.7B). However, when FtsH-S6 ATPase is 
titrated into a gankyrin/GBP7.19 complex, we observe dramatically decreased affinity (F gure 
5.7C). This finding suggests that GBP7.19 likely binds the concave face of gankyrin and therefore 
is in a position to block the gankyrin/S6 ATPase interaction. The dramatic change in enthalpy (ΔH 
=-29 kcal/mol for the titration of S6 ATPase into gankyrin; ΔH =-14 kcal/mol for the titration of 
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S6 ATPase into pre-complexed gankyrin/GBP7.19) also suggests an altered mode of binding 
between S6 ATPase and gankyrin, possibly due to GBP7.19 blocking a portion of the protein-
protein interface found in the native S6 ATPase/gankyrin complex. 
 
5.6 GBP7.19 Suppresses Gankyrin/MDM2-Dependent Ubiquitination of p53  
We next set out to determine if GBP7.19 modulates gankyrin- and MDM2-dependent p53 
ubiquitination – a principal disease-relevant role for this oncoprotein. As stated above, gankyrin 
binds the E3 ubiquitin ligase MDM2, and in doing so increases the extent to which p53 is 
polyubiquitinated. Ultimately, this leads to decreased cellular levels of p53 and suppression of 
p53-dependent apoptosis. We used a commercially available in vitro assay (MDM2/p53 
Ubiquitination Kit, BostonBiochem) to measure p53 ubiquitination without gankyrin, with 
gankyrin, or with gankyrin and varied concentrations of GBP7.19. Briefly, p53 was mixed with 
the ubiquitination cocktail (reaction buffer, E1, E2, MDM2, Mg2+-ATP, ubiquitin) and native p53 
was measured by Western blot. As expected, only ~68% of native p53 is present following the 
Figure 5.7 (A) S6 ATPase (red) superimposed on the C-terminal ATPase domain of FtsH. (B) ITC data
for an experiment that involves titrating FtsH-S6 ATPase into gankyrin (KD ~67 nM). (C) ITC data for an











































































ubiquitination reaction (Figure 5.8A and Figure 5.8B, lane 2), compared to a control experiment 
where no ubiquitin is added (Figure 5.8A and Figure 5.8B, lane 1). Adding 1 equivalent of 
gankyrin to the ubiquitination cocktail (relative to MDM2) resulted in a significant reduction in 
the level of native (unubiquitinated) p53 (Figure 5.8A and Figure 5.8B, lane 3), compared to the 
ubiquitination reaction that lacks gankyrin (Figure 5.8A and Figure 5.8B, lane 2). Addition of 
GBP7.19 results in decreased ubiquitination of p53. When 0.25, 0.5, or 1 equivalents of GBP7.19 
is added to the ubiquitination cocktail (relative to gankyrin and MDM2), we observe a 
concentration-dependent and dramatic increase in the levels of native p53 (Figure 5.8A and 
Figure 5.8B, lanes 4-6). One equivalent of GBP7.19 completely inhibits p53 ubiquitination. One 
possible explanation for this observation is that GBP7.19 binds the gankyrin/MDM2 complex (as 





5.7 Conclusion  
Gankyrin is a recently reported ankyrin repeat oncoprotein whose overexpression is 
directly linked to the onset, proliferation, and/or metastasis of a number of cancers. In forming a 
complex with MDM2 gankyrin increases the extent to which p53 is polyubiquitinated, leading to 
suppression of p53-dependent apoptosis and cell cycle deregulation in gankyrin overexpressing 
cells. 
Collectively, the findings in this chapter can be summarized as follows: using error-prone 
PCR, DNA shuffling, yeast display screening, and protein engineering, we were able to 
dramatically optimize a PPI involving the oncoprotein gankyrin and synthetic gankyrin-binding 
proteins (GBPs). The most active protein we identified (GBP7.19) bind gankyrin very tightly (KD 
~21 nM), modulate a physiologically-relevant interaction involving gankyrin and S6 ATPase, and 
dramatically decrease gankyrin/MDM2-dependent ubiquitination of p53, a principal disease-
relevant function of gankyrin. 
 The proteins reported in this chapter represent the most potent gankyrin-binding reagents 
known to date, establish GBP7.19 as a viable tool to study gankyrin-dependent cellular processes, 




Protein Purification Gankyrin-binding proteins (GBPs) were amplified using oligonucleotides 
and cloned into a pET plasmid using restriction enzymes BamHI and PacI, resulting in N-terminal 
His6x-tagged constructs, which were confirmed by DNA sequencing (all constructs in this 
manuscript were confirmed by GENEWIZ, South Plainfield, NJ). GBP mutants were made using 
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site-directed mutagenesis. These constructs were transformed into BL21s (DE3). Gankyrin was 
cloned into a pET plasmid using restriction enzymes NcoI and PacI, resulting in a C-terminally 
His6x -tagged construct, and transformed into BL21s (DE3). A gankyrin construct with a C-
terminal Avi-tag (termed gankyrin-Avi) was also made in this fashion. Cells were grown in 1-2.5 
L LB cultures containing carbenicillin at 37 °C to OD600 ~0.5 and induced with 1 mM IPTG at 25 
°C for 8 hours. Cells were then collected by centrifugation, resuspended in phosphate buffer (20 
mM sodium phosphate pH 7.4, 150 mM NaCl) or HEPES buffer (20 mM HEPES pH 7.5, 150 mM 
NaCl, 1mM DTT) with protease inhibitor tablets (Roche) and stored at -20 °C. Frozen pellets were 
thawed and sonicated for 2 minutes. The lysate was cleared by centrifugation (8000 rpm, 20 
minutes) and the supernatant was mixed with 1 mL of Ni-NTA agarose resin for 1 hour. The resin 
was collected by centrifugation (4750 rpm, 5 minutes). The resin was washed with 50 mL of buffer 
containing 20 mM imidazole, followed by 10 mL buffer containing 50 mM imidazole. Proteins 
were then eluted with 5 mL buffer containing 400 mM imidazole. The proteins were dialyzed 
against buffer and analyzed for purity by SDS-PAGE. Purified proteins were quantified using 
absorbance at 280 nm and confirmed with a modified Lowry Assay. 
 
Biotinylation Gankyrin-Avi (purified as shown above) was biotinylated using the BirA-biotin 
ligase kit (Avidity). Briefly, 40 M gankyrin-Avi was biotinylated in a 1 mL reaction (containing 
Biomix A and Biomix B) at 30 °C for 45 minutes using 1.0 L 3 mg/mL BirA. After extensive 
dialysis in HEPES buffer to remove biotin, complete biotinylation was confirmed by mass 




Protein Library Preparation EBY100 yeast (trp-, leu-, with the Aga1p gene stably integrated) 
and the pCTCON2 plasmid were generously provided by the Wittrup lab (MIT). The gene 
encoding gankyrin-binding protein 7 (GBP7) was amplified by PCR cloned into pCTCON2 in-
frame with Aga2, an N-terminal HA-tag, and a C-terminal myc tag, using the restriction enzymes 
NheI and BamHI. When analyzed for display only, GBP7 displayed efficiently on EBY100 cells 
(~75 %). To construct the error-prone PCR library, homologous recombination (referred to as HR 
herein) primers were designed for pCTCON2 so that each primer sequence overlapped with ~40 
bases on the plasmid. Random mutations were introduced into GBP7 using the Genemorph II 
random mutagenesis kit (Agilent). DNA shuffling was used in the final round as the diversification 
method. Briefly, 5 g of amplified insert was digested with 1 L DNase I (Sigma-Aldrich, diluted 
1:1000 in 20 mM Tris-HCl pH 8.0, 5 mM CaCl2, 50 % glycerol) in 50 mL 20 mM Tris-HCl pH 
8.0 and 10 mM MnCl2 for 2 minutes at 15 °C. The reaction was immediately transferred to 90 °C 
for 10 minutes to stop DNA cleavage, and then ran on a 3 % agarose gel. A smear from ~50-200 
bases was extracted. A modified PCR was ran (10 cycles without primers, then 40 cycles with HR 
primers) using the digested fragments as a template, which generated the DNA shuffled library. 
 
Yeast Display Screening Approximately 2 g of double digested (NheI and BamHI) pCTCON2 
plasmid and 5 g amplified library (with HR overhangs) were mixed and transformed via 
electroporation into 50 L of electrocompetent EBY100 using 2 mm cuvettes, and immediately 
rescued with 1 mL pre-warmed YPD for 2 hours at 30 °C. After rescue, yeast was centrifuged at 
1,300 g for 1 minute and supernatant YPD was removed. Yeast was suspended in 50 mL fresh SD-
CAA (5.4 g/L Na2HPO4, 8.6 g/L NaH2PO4 • H2O, 20 g/L dextrose, 6.7 g/L yeast nitrogen base w/o 
amino acids, 5 g/L casamino acids, 100 kU/L penicillin, 0.1 g/L streptomycin), plated by serial 
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dilution onto SD-CAA plates (SD-CAA with 182 g/L sorbitol and 15 g/L agar), and incubated at 
30 °C. After 3 days, colonies were counted, resulting in libraries of 1-2 x 107. Yeast was sub-
cultured to 0.5 x 107 cells/mL in 50 mL SD-CAA and grown to an OD600 = 2.0. Yeast were then 
sub-cultured at a concentration of 1 x 107 cells/mL in SG-CAA (galactose containing), and induced 
at 25 °C for 48 hours (shaking at 250 rpm). Yeast was washed 1 time with 4 °C PBS-BSA, and 
incubated with biotinylated gankyrin and competitors (Pdar and p16INK4a in rounds 5 and 6, 
concentrations are provided below) in PBS-BSA for 1 hour at 25 °C. After 30 minutes, a FITC-
conjugated anti-myc antibody was added at 1:250, and incubation was continued. The yeast was 
washed 1 time, and then incubated with streptavidin-R-phycoerythrin (SAPE) at 1:100 for 1 hour 
on ice. After a final wash, yeast were resuspended and double-positive (FITC for display and PE 
for binding) yeast were sorted into 5 mL SD-CAA using a MoFlo Flow Cytometer (Beckman 
Coulter, CSU Proteomics and Metabolomics Facility). Compensation was done to assure no 
overlap in FITC and PE emission. Sort gates were set to take ~1% of the healthy cell population, 
in order to maintain maximum stringency in both display and binding. Gates were set to enrich for 
cells that display the best (indicating protein stability) and bind the tightest. Sorted yeast were 
transferred to 50 mL pre-warmed SD-CAA and incubated at 30 °C for 3 days at 250 rpm. Plasmid 
DNA was recovered from the sorted yeast using a Zymoprep Yeast Plasmid Miniprep II kit (Zymo 
Research). DNA was either used as template for the next round of diversification, or transformed 
into 5 E. coli in order to sequence library members. 
 
Enzyme-Linked Immunosorbent Assay (ELISA) GBPs were cloned into a pET plasmid with 
N-terminal His6x-tags and C-terminal FLAG-tags (DYKDDDDK) and purified as described 
previously. 100 L of biotinylated gankyrin was incubated at 25 °C for 2 hours on streptavidin-
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coated plates (Pierce) at a concentration of 10 g/mL in HEPES buffer. Wells were washed 3 times 
with 200 L wash buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM DTT, 0.05 % Tween-20, 
0.01 mg/mL BSA). 100 L of each GBP variant was incubated at 25 nM for 1 hour at 25 °C, and 
then washed 3 times. An HRP-conjugated anti-FLAG antibody (Abcam) was incubated at 1:5000 
in Odyssey blocking buffer (Li-Cor) for 1 hour at 25 °C, and then washed 3 times. Colorimetry 
was developed using TMB-One substrate and absorbance was measured at 655 nm on a plate 
reader (SynergyMx BioTek). 
 
Lysate Ni-NTA Pull-down Assay Gankyrin was cloned into MCS1 of pETDuet using restriction 
enzymes BamHI and HindIII, resulting in N-terminal His6x-tagged gankyrin. GBP7.19 was cloned 
into MCS2 of pETDuet using the restriction enzymes NdeI and PacI. Completed constructs were 
transformed into BL21s (DE3). Cells containing the co-expressed pair were inoculated and 
induced as described previously. Cells were spun down and resuspended in lysis buffer (20 mM 
sodium phosphate pH 7.4, 150 mM NaCl, 1 mM DTT), lysed by sonication, and spun down to 
remove cell debris. Cleared lysate was incubated with 100 L Ni-NTA agarose resin for 45 
minutes. Ni-NTA agarose was washed with 5 mL lysis buffer and 5 mL lysis buffer with 20 mM 
imidazole. Proteins were eluted with lysis buffer containing 400 mM imidazole. The pull-down 
was analyzed by SDS-PAGE and coomassie staining. 
 
Isothermal Titration Calorimetry Isothermal titration calorimetry (ITC) was performed using a 
MicroCal iTC200 calorimeter maintained at 25 °C. All proteins were purified by standard methods, 
using a His6x tag. Purified proteins were dialyzed extensively in phosphate buffer (20 mM sodium 
phosphate pH 7.4, 150 mM NaCl, 2.5 mM 2-mercaptoethanol). GBP variants were placed in the 
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sample cell at concentrations ranging from 10-15 M, and 100-150 M of gankyrin was titrated 
in 2.49 mL increments (16 injections total), with an initial injection of 0.4 L, at 180 second 
intervals using a stirring speed of 750 rpm. Heats of dilution were measured in the same manner 
described above, separately titrating buffer into buffer and gankyrin into buffer. CoA-binding 
studies were performed by titrating 100 M of gankyrin into a 1:1 mix of GBP7.17 and CoA (10 
M each), or by titrating 100 M GBP7.17 into the sample cell containing 10 M CoA. 
Displacement experiments were performed by titrating 100 M FtsH-S6 ATPase into a pre-formed 
1:1 complex of gankyrin and GBP7.19 (10 M each). Data were analyzed using Origin7.0 
(MicroCal, iTC200) using a one set of sites binding model for fitting. All data were reference 
subtracted by subtracting the mean heat of dilution from each data point. 
 
p53 Ubiquitination Assay Gankyrin-dependent ubiquitination of p53 was obtained, by modifying 
a commercially available assay (MDM2/p53 Ubiquitination Kit, BostonBiochem). Briefly, 1 M 
gankyrin was added to standard 30 L reactions (contents include reaction buffer, p53, E1, E2, 
MDM2, Mg2+-ATP), along with varying concentrations of GBP7.19. Ubiquitin was added to start 
the reactions, and run at 25 °C for 1 hour. The reactions were terminated with 8 L loading dye 
and 2 L 1M DTT, and ran on 10 % Ready Gel precast gels (Biorad) at 160 V for 1 hour. The gel 
was transferred to a PVDF membrane with the iBlot gel transfer station (Invitrogen). The 
membrane was blocked for 30 minutes with 5 % milk in PBS, and then incubated with provided 
-p53 anitbody (1:2000) in Odyssey Blocking Buffer (Li-Cor) for 1 hour at 25 °C. The membrane 
was then washed 3 times with PBS-Tween, rinsed with PBS, then incubated with an Alexa Fluor 
790-conjugated anti-mouse secondary antibody (Abcam) for 1 hour at 25 °C, followed by 
extensive washing. Membrane was imaged using an Odyssey CLx Near IR Scanner (Li-Cor), and 
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densitometry was performed for each lane using ImageJ (NIH). Statistical analysis was performed 
with GraphPad. 
 























































































5.10 Primers Used in This Work 
All DNA primers are listed 5' to 3' 
 
Prb (GBP) FP: CGCGGATCCGGGCAGCACCCGTCCGATT 
Prb (GBP) RP: CCTTAATTAATTATTTTTCGCCCAGCAGGCGTTC 
GBP7.17 Y55N FP: GTCTATCCTGTAAACCCGAATTATGAAGAAGTGCTGG 
GBP7.17 Y55N RP: CCAGCACTTCTTCATAATTCGGGTTTACAGGATAGAC 
GBP7.17 C132R RP: CCTTAATTAATTATTTTTCGCCCAGCAGGCGTTCGTGCTCACGCA 
TCATACAGCG 
GBP7.17 G79D FP: GATAAAATTGAGGTCGTAGATCTGTTTGTGTACCCGATTTG 
GBP7.17 G79D RP: CAAATCGGGTACACAAACAGATCTACGACCTCAATTTTATC 
GBP7.17 R110H FP: GTTTCAGCACAACACATATCATGGGGAGGCTGGACGTCAAG 
GBP7.17 R110H RP: CTTGACGTCCAGCCTCCCCATGATATGTGTTGTGCTGAAAC 
GBP7.17 C93Y FP: CGACGGAGTTCGTTGTCTATGCCATCAAGAAAGGGGC 
GBP7.17 C93Y RP: GCCCCTTTCTTGATGGCATAGACAACGAACTCCGTCG 
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GBP7.17 E112V FP: GCACAACACATATCGTGGGGTGGCTGGACGTCAAGCCAAGG  
GBP7.17 E112V RP: CCTTGGCTTGACGTCCAGCCACCCCACGATATGTGTTGTGC 
GBP7.17 E57K FP: CCTGTAAACCCGTATTATAAAGAAGTGCTGGGCCGCAAG 
GBP7.17 E57K RP: CTTGCGGCCCAGCACTTCTTTATAATACGGGTTTACAGG 
Gankyrin FP NcoI: CATGCCATGGAGGGGTGTGTGTCTAACATAATGATCTGTAACC 
Gankyrin RP PacI: CCTTAATTAATTAGTGATGGTGGTGGTGATGACCCATAGAAGCCT 
CTTCACCTTCTG  
HR FP NheI: CTCTGGTGGAGGCGGTAGCGGAGGCGGAGGGTCGGCTAGC 
HR RP BamHI: CGAGCTATTACAAGTCCTCTTCAGAAATCAGCTTTTGTTCGGATCC 
 








Gankyrin-Avi Predicted Mass: 27946 Da 
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Aga agglutinin protein  
Ala/A alanine 
APC antigen-presenting cell 
Arg/R arginine 
Asn/N asparagine 
Asp/D aspartic acid 
ATP adenosine triphosphate 
AvNAPSA average neighboring atoms per side chain atom  
BLIP -lactamase inhibitor protein 
bp base pair 
BSA bovine serum albumin 
CaM calmodulin 
CD circular dichroism 
CDK4 cyclin-dependent kinase 4 
CDR complementary determining region 
Cfu colony forming unit 




DHFR dihydrofolate reductase 
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DLS dynamic light scattering 
DNA deoxyribonucleic acid 
DSC differential scanning calorimetry 
DTT dithiothreitol  
ELISA enzyme-linked immunosorbent assay 
ep-PCR error-prone polymerase chain reaction 
FACS fluorescence-activated cell sorting 
FDA Food and Drug Administration 
FITC fluorescein isothiocyanate  
frGFP folding reporter green fluorescent protein 
GBP gankyrin-binding protein 
GFP green fluorescent protein 
Gln/Q glutamine 
Glu/E glutamic acid 
Gly/G glycine 
HEL hen egg lysozyme 
hGH human growth hormone 
His/H histidine 
HIV human immunodeficiency virus 
HRP horseradish peroxidase  





ITC isothermal titration calorimetry 
KD dissociation constant  
Leu/L leucine 
Lys/K lysine  
MCS multiple cloning site 
MDM2 murine double minute 2 
Met/M methionine 
MHC major histocompatibility complex 
MRSA methicillin-resistant Staphylococcus aureus  
NHR N-heptad repeat 
NTA nitrilotriacetic acid 
NTF3 neurotrophin-3  
PAGE polyacrylamide gel electrophoresis 
PAK1 p21-activated kinase 1 
PBS phosphate-buffered saline 
PCA protein-fragment complementation assay 
PCR polymerase chain reaction 
PDB protein data bank 
PE phycoerythrin 
PEG polyethylene glycol 
PH Domain pleckstrin homology domain 
Phe/F phenylalanine 




pRb phosphorylated retinoblastoma protein 
RT room temperature 
RPM revolutions per minute 
SAPE streptavidin-R-phycoerythrin 
SDS sodium dodecyl sulfate 
Ser/S serine 
sfGFP superfolder green fluorescent protein 
SHV-1 sulfhydryl variable-1 
smMLCK smooth muscle myosin light chain kinase  
spGFP superpositive green fluorescent protein 
TALEN transcription activator-like nucleases 
TAT trans-activating transcriptional activator  
TEM-1 temoneira-1 
Thr/T threonine 
TMB 3, 3ʹ, 5, 5ʹ-tetramethylbenzidine 
Trp/W tryptophan 
Tyr/Y tyrosine 
Val/V valine 
 
